

www.sughrue.com

09/890463



SUGHRUE MION ZINN MACPEAK & SEAS, PLLC

Gordon Kit

T 202-663-7945
gkit@sughrue.com



August 1, 2001

BOX PCT

Commissioner for Patents
Washington, D.C. 20231

PCT/AU00/00056 - filed
February 2, 2000

Re: Application of **Ove HOECH-GULDBERG**
and **Sophie DOVE** entitled "**PIGMENT
PROTEIN FROM CORAL TISSUE**"
Our Ref: Q-65619

Dear Sir:

The following documents and fees are submitted herewith in connection with the above application for the purpose of entering the National stage under 35 U.S.C. § 371 and in accordance with Chapter II of the Patent Cooperation Treaty:

- ☐ an executed Declaration and Power of Attorney.
- ☐ an English translation of the International Application.
- ☒ 10 sheets of drawings.
- ☐ an English translation of Article 19 claim amendments.
- ☒ International Preliminary Examination Report.
- ☐ an executed Assignment and PTO 1595 form.
- ☐ a Form PTO-1449 listing the ISR references, and a complete copy of each reference.
- ☒ a Preliminary Amendment
- ☒ Sequence Listing.

The Declaration and Power of Attorney, Assignment, Small Entity Status Declaration, Form PTO-1449 listing the International Search Report (ISR), along with a complete copy of each reference, will be submitted at a later date.

Priority is claimed from February 2, 1999, based on Australian Application No. PP8463.



Sughrue

SUGHRUE MION ZINN MACPEAK & SEAS, PLLC

JC17 Rec'd PCT/PTO 01 AUG 2001

09/890463

Commissioner for Patents

August 1, 2001

Page 2

It is assumed that copies of the International Application, the International Search Report, the International Preliminary Examination Report, and any Articles 19 and 34 amendments as required by § 371(c) will be supplied directly by the International Bureau. However, for the Examiner's convenience, submitted herewith with the International Application and International Preliminary Examiner Report.

Applicant claims benefit of small entity status in accordance with 37 CFR § 1.27.


The Government filing fee is calculated as follows:

| | | |
|------------------------------|--------------|---------------------|
| Total claims | 68 - 20 = 48 | x \$9.00 = \$432.00 |
| Independent claims | 4 - 3 = 1 | x \$40.00 = \$40.00 |
| Base Fee | | \$500.00 |
| Multiple Dependent Claim Fee | | \$135.00 |
| TOTAL FEE | | \$1107.00 |

The Commissioner is hereby authorized to charge the statutory filing fee, in the amount of \$1,107.00, to Deposit Account No. 19-4880.

The Commissioner is also hereby directed and authorized to charge or credit any difference or overpayment to Deposit Account No. 19-4880. The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.492 which may be required during the entire pendency of the application to Deposit Account No. 19-4880. A duplicate copy of this transmittal letter is attached.

Respectfully submitted,



Gordon Kie

Registration No. 30,764

09/890463

Applicant or

Patentee:

Ove HOECH-GULDBERG and Sophie DOVE

Attorney's Docket

No. Q-65619

Application or

Patent No.

09/890,463

Filed or Issued:

August 1, 2001

For:

PIGMENT PROTEIN FROM CORAL TISSUE

**VERIFIED STATEMENT (DECLARATION) CLAIMING
SMALL ENTITY STATUS (37 CFR 1.9(f) and 1.27 (c)) --**

NONPROFIT ORGANIZATION

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF ORGANIZATION

THE UNIVERSITY OF SYDNEY

ADDRESS OF

Sydney, New South Wales 2006,

ORGANIZATION

AUSTRALIA

TYPE OF ORGANIZATION

☒ University or other institution of higher education

☐ Tax exempt under Internal Revenue Service Code (26 USC 501(a)) and 501(c) (3))

☐ Nonprofit scientific or educational under statute of state of The United States of America

(Name of State)

(Citation of statute)

☐ Would qualify as tax exempt under Internal Revenue Service Code (26 USC 501(a) and 501(c) (30)) if located in

The United States of America

☐ Would qualify as nonprofit scientific or educational under statute of state of The United States of America if located in

The United States of America

(Name of State)

(Citation of statute)

I hereby declare that the above nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9(e) for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code with regard to the invention entitled: **PIGMENT PROTEIN FROM CORAL TISSUE** by inventors **Ove HOECH-GULDBERG and Sophie DOVE**.

Described in

☐ the specification filed herewith

☒ application no. **09/890,463**

filed

August 1, 2001

☐ patent no.

issued

I hereby declare that rights under contract or law have been conveyed to and remain with the nonprofit organization with regard to the above identified invention.

If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 CFR 1.9(d) or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

*NOTE: Separate verified statement are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27)

FULL NAME _____

ADDRESS _____

☐ INDIVIDUAL

☐ SMALL BUSINESS
CONCERN

☐ NONPROFIT
ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING Kevin Craft.

TITLE IN ORGANIZATION Acting Director, Business Liaison Office

ADDRESS OF PERSON SIGNING The University of Sydney, NSW, 2006, Australia

Signature  Date 31/8/01

Rec'd PCT/PTO 09 NOV 2001

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#5/
C

In re Application of:

Ove HOECH-GULDBERG et al

Appln. No.: 09/890,463

Group Art Unit: 0000

Filed: August 1, 2001

Examiner: Unknown

For: PIGMENT PROTEIN FROM CORAL TISSUE

THIRD PRELIMINARY AMENDMENT

Assistant Commissioner
of Patents
Washington, D.C. 20231

Sir:

Supplemental to the Preliminary Amendment filed August 1, 2001, and the Supplemental Preliminary Amendment filed August 27, 2001, and prior to examining the above-identified application, please amend the application as follows:

IN THE SEQUENCE LISTING:

Please delete the present Sequence Listing and insert the substitute Sequence Listing filed simultaneously herewith.


REMARKS

Applicants file simultaneously herewith a substitute Sequence Listing in PatentIn Version 3.1, (which is considered to be a separate document by the U.S. Patent and Trademark Office) in order to correct minor formatting errors within the present Sequence Listing. Hence, the submission of a substitute Sequence Listing does not constitute new matter, and thus entry is requested.

PRELIMINARY AMENDMENT
U.S. Appln. No. 09/890,463

The Examiner is invited to contact the undersigned at his Washington telephone number on any questions which might arise.

Respectfully submitted,



Gordon Kit
Registration No. 30,764

SUGHRUE MION, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3202
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

Date: November 9, 2001

A P P E N D I X

Marked-up Version of Changes

IN THE SEQUENCE LISTING:

The present Sequence Listing is being replaced by the substitute Sequence Listing filed simultaneously herewith.

SEQUENCE LISTING

<110> HOECH-GULDBERG, Ove
DOVE, Sophie

<120> PIGMENT PROTEIN FROM CORAL TISSUE

<130> Q-65619

<140> 09/890,463

<141> 2000-08-01

<150> PCT/AU00/00056

<151> 2000-02-02

<150> PP8463

<151> 1999-02-02

<160> 15

<170> PatentIn version 3.1

<210> 1

<211> 5

<212> PRT

<213> Acropora aspera, Acropora horrida, Montipora caliculata, Porites murrayensis,
Montipora monasteriata and Porites lobata

<400> 1

Ser Val Ile Ala Lys

1 5

<210> 2

<211> 17

<212> PRT

<213> Acropora horrida

<400> 2

Ser Val Ile Ala Lys Gln Met Thr Tyr Lys Val Tyr Met Ser Gly Thr
1 5 10 15

Val

<210> 3

<211> 231

<212> PRT

<213> Acropora aspera

<400> 3

Ser Val Ile Ala Lys Gln Met Thr Tyr Lys Val Tyr Met Ser Gly Thr

| | | | |
|---|-----|-----|-----|
| 1 | 5 | 10 | 15 |
| Val Asn Gly His Tyr Phe Glu Val Glu Gly Asp Gly Lys Gly Lys Pro | 20 | 25 | 30 |
| Tyr Glu Gly Glu Gln Thr Val Arg Leu Ala Val Thr Lys Gly Gly Pro | 35 | 40 | 45 |
| Leu Pro Phe Ala Trp Asp Ile Leu Ser Pro Gln Cys Gln Tyr Gly Ser | 50 | 55 | 60 |
| Ile Pro Phe Thr Lys Tyr Pro Glu Asp Ile Pro Asp Tyr Val Lys Gln | 65 | 70 | 75 |
| Ser Phe Pro Gly Arg Tyr Thr Trp Glu Arg Ile Met Asn Phe Glu Asp | 85 | 90 | 95 |
| Gly Ala Val Cys Thr Val Ser Asn Asp Ser Ser Ile Gln Gly Asn Cys | 100 | 105 | 110 |
| Phe Ile Tyr His Val Lys Phe Ser Gly Leu Asn Phe Pro Pro Asn Gly | 115 | 120 | 125 |
| Pro Val Met Gln Lys Lys Thr Gln Gly Trp Glu Pro Asn Thr Glu Arg | 130 | 135 | 140 |
| Leu Phe Ala Arg Asp Gly Met Leu Ile Gly Asn Asn Phe Met Ala Leu | 145 | 150 | 155 |
| Lys Leu Glu Gly Gly Gly His Tyr Leu Cys Glu Phe Lys Ser Thr Tyr | 165 | 170 | 175 |
| Lys Ala Arg Lys Pro Val Lys Met Pro Gly Tyr His Tyr Val Asp Arg | 180 | 185 | 190 |
| Lys Leu Asp Val Thr Asn His Asn Lys Asp Tyr Thr Ser Val Glu Gln | 195 | 200 | 205 |
| Arg Glu Ile Ser Ile Ala Arg Lys Pro Leu Val Ala Cys Cys Phe Phe | 210 | 215 | 220 |
| Arg Val Lys Ser Arg His Lys | 225 | 230 | |

<210> 4
<211> 235
<212> PRT
<213> Acropora aspera

<400> 4

Ser Val Ile Ala Lys Gln Met Thr Tyr Lys Val Tyr Met Ser Gly Thr
1 5 10 15

Val Asn Gly His Tyr Phe Glu Val Glu Gly Asp Gly Lys Gly Lys Pro
20 25 30

Tyr Glu Gly Glu Gln Thr Val Arg Leu Ala Val Thr Lys Gly Gly Pro
35 40 45

Leu Pro Phe Ala Trp Asp Ile Leu Ser Pro Gln Cys Gln Tyr Gly Ser
50 55 60

Ile Pro Phe Thr Lys Tyr Pro Glu Asp Ile Pro Asp Tyr Val Lys Gln
65 70 75 80

Ser Phe Pro Gly Arg Tyr Thr Trp Glu Arg Ile Met Asn Phe Glu Asp
85 90 95

Gly Ala Val Cys Thr Val Ser Asn Asp Ser Ser Ile Gln Gly Asn Cys
100 105 110

Phe Ile Tyr His Val Lys Phe Ser Gly Leu Asn Phe Pro Pro Asn Gly
115 120 125

Pro Val Met Gln Lys Lys Thr Gln Gly Trp Glu Pro Asn Thr Glu Arg
130 135 140

Leu Phe Ala Arg Asp Gly Met Leu Ile Gly Asn Asn Phe Met Ala Leu
145 150 155 160

Lys Leu Glu Gly Gly Gly His Tyr Leu Cys Glu Phe Lys Ser Thr Tyr
165 170 175

Lys Ala Lys Lys Pro Val Lys Met Pro Gly Tyr His Tyr Val Asp Arg
180 185 190

Lys Leu Asp Val Thr Asn His Asn Lys Asp Tyr Thr Ser Val Glu Gln
 195 200 205

Cys Glu Ile Ser Ile Ala Arg Lys Pro Val Val Ala Cys Arg Phe Phe
 210 215 220

Arg Val Lys Ser Arg His Lys Tyr Ala Val Ala
 225 230 235

<210> 5
 <211> 841
 <212> DNA
 <213> Acropora aspera

<400> 5
 tccggttatcg ctaaacagat gacctacaaa gtttatatgt caggcacggt caatggacac 60
 tactttgagg tcgaaggcga tggaaaagga aagccttacg agggggagca gacggtaagg 120
 ctggctgtca ccaagggcgg acctctgcc tttgcttggg atattttatc accacagtgt 180
 cagtacggaa gcataccatt caccaagtac cctgaagaca tccctgacta tgtaaagcag 240
 tcattcccg ggagatatac atgggagagg atcatgaact ttgaagatgg tgcagtgtgt 300
 actgtcagca atgattccag catccaaggc aactgtttca tctaccatgt caagttctct 360
 ggtttgaact ttcctcccaa tggacctgtt atgcagaaga agacacaggg ctgggaaccc 420
 aacactgagc gtctctttgc acgagatgga atgctgatag gaaacaactt tatggctctg 480
 aggttagaag gaggtggtca ctatttgtgt gaattcaa ctacttaca ggcaaggaag 540
 gctgtgaaga tgccagggt tcaactatgtt gaccgcaaac tggatgtaac caatcacaac 600
 aaggattaca cttccgttga gcagcgtgaa atttccattg cacgcaaacc tttggtcgcc 660
 tgctgttttt tcagagtcaa atcaaggcac aaataagcag tggcgtaaaa aacgtagatt 720
 ctgatttttag cttagagaag taggaacgaa gaagtgtaga caaccttcaa tgattaaact 780
 tttgaaaaca acsccaaaaa aaaaaaaaaa aaaaaaaaaa aaaaagcggc cgctcgaatt 840
 a 841

<210> 6
 <211> 841
 <212> DNA
 <213> Acropora aspera

<400> 6
 tccggttatcg ctaaacagat gacctacaaa gtttatatgt caggcacggt caatggacac 60

tactttgagg tcgaaggcga tggaaaagga aagccttacg aggggggagca gacggtaagg 120
ctggctgtca ccaagggcgg acctctgcca ttgcttggg atattttatc accacagtgt 180
cagtacggaa gcataccatt caccaagtac cctgaagaca tccctgacta tgtaaagcag 240
tcattcccgg ggagatatatac atgggagagg atcatgaact ttgaagatgg tgcagtgtgt 300
actgtcagca atgattccag catccaaggc aactgtttca tctaccatgt caagttctct 360
ggtttgaact ttcctcccaa tggacctgtt atgcagaaga agacacaggg ctgggaaccc 420
aacactgagc gtctctttgc acgagatgga atgctgatag gaaacaactt tatggctctg 480
aagttagaag gaggtggtca ctatttgtgt gaattcaaat ctacttacia ggcaaagaag 540
cctgtgaaga tgccagggtta tcactatgtt gaccgcaaac tggatgtaac caatcacaac 600
aaggattaca cttccgttga gcagtgtgaa atttccattg cacgcaaacc tgtggtcgcc 660
tgccgttttt tcagagtcaa atcaaggcac aaatacgcag tggcgtaaaa aacgtagatt 720
ctgatttttag cttatagaag taggaacgaa gaagtgtaaa caaccattaa tgattaaact 780
tttgaaaaca acgccataaa aaaaaaaaaa aaaaaaaaaa aaaaagcggc cgctcgaatt 840
a 841

<210> 7

<211> 18

<212> PRT

<213> Acropora aspera, Montipora caliculata and Porites murrayensis

<400> 7

Ser Val Ile Ala Lys Gln Met Thr Tyr Lys Val Tyr Met Ser Gly Thr
1 5 10 15

Val Asn

<210> 8

<211> 25

<212> PRT

<213> Porites lobata

<400> 8

Ser Val Ile Ala Lys Gln Met Thr Tyr Lys Val Tyr Met Ser Gly Thr
1 5 10 15

Val Asn Asn His Tyr Glu Phe Val Thr
20 25

<210> 9
<211> 225
<212> PRT
<213> Discosoma sp.

<400> 9

Met Arg Ser Ser Lys Asn Val Ile Lys Glu Phe Met Arg Phe Lys Val
1 5 10 15

Arg Met Glu Gly Thr Val Asn Gly His Glu Phe Glu Ile Glu Gly Glu
20 25 30

Gly Glu Gly Arg Pro Tyr Glu Gly His Asn Thr Val Lys Leu Lys Val
35 40 45

Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp Ile Leu Ser Pro Gln
50 55 60

Phe Gln Tyr Gly Asn Lys Val Tyr Val Lys His Pro Ala Asp Ile Pro
65 70 75 80

Asp Tyr Lys Lys Leu Ser Phe Pro Glu Gly Phe Lys Trp Glu Arg Trp
85 90 95

Met Asn Phe Glu Asp Gly Gly Val Val Thr Val Thr Gln Asp Ser Ser
100 105 110

Leu Gln Asp Gly Cys Phe Ile Tyr Lys Val Lys Phe Ile Gly Val Asn
115 120 125

Phe Pro Ser Asp Gly Pro Val Met Gln Lys Lys Thr Met Gly Trp Glu
130 135 140

Ala Ser Thr Lys Arg Leu Tyr Pro Arg Asp Gly Val Leu Lys Gly Glu
145 150 155 160

Ile His Lys Ala Leu Lys Leu Lys Asp Gly Gly His Tyr Leu Val Glu
165 170 175

Phe Lys Ser Ile Tyr Met Ala Lys Lys Pro Val Gln Leu Pro Gly Tyr
180 185 190

Tyr Tyr Val Asp Ser Lys Leu Asp Ile Thr Ser His Asn Glu Asp Tyr
195 200 205

Thr Ile Val Glu Gln Tyr Glu Arg Thr Glu Gly Arg His His Leu Phe
210 215 220

Leu
225

<210> 10
<211> 230
<212> PRT
<213> Discosoma sp.

<400> 10

Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val
1 5 10 15

Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu
20 25 30

Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys
35 40 45

Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Phe
50 55 60

Ser Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Arg
65 70 75 80

His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg
85 90 95

Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val
100 105 110

Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
115 120 125

Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn
130 135 140

Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly
145 150 155 160

Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val
165 170 175

Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro
180 185 190

Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser
195 200 205

Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val
210 215 220

Thr Ala Ala Gly Ile Thr
225 230

<210> 11
<211> 20
<212> DNA
<213> Artificial

<220>
<221> misc_feature
<223> PCR Primers

<400> 11
tcggttatcg ctaaacagat

20

<210> 12
<211> 20
<212> DNA
<213> Artificial

<220>
<221> misc_feature
<223> PCR Primers

<400> 12
tttgtgcctt gatttgactc

20

<210> 13
<211> 20
<212> DNA
<213> Artificial

<220>
<221> misc_feature

<223> PCR Primers

<400> 13
cgccactgcg tatttggtgcc

20

<210> 14
<211> 20
<212> DNA
<213> Artificial

<220>
<221> misc_feature
<223> PCR Primers

<400> 14
ggcgaccaca ggtttgctg

20

<210> 15
<211> 30
<212> DNA
<213> Artificial

<220>
<221> misc_feature
<223> PCR Primers

<400> 15
tcggttatcg ctaaacagat gacctacaaa

30



5620

JC14 Rec'd PCT/PTO 27 AUG 2001

PCT

PATENT APPLICATION

#4/B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ove HOECH-GULDBERG et al

Appln. No.: 09/890,463

Group Art Unit: 0000

Filed: August 1, 2001

Examiner: Unknown

For: PIGMENT PROTEIN FROM CORAL TISSUE

SUPPLEMENTAL PRELIMINARY AMENDMENT

RECEIVED

03 OCT 2001

Legal Staff
International Division

Assistant Commissioner
of Patents
Washington, D.C. 20231

Sir:

Supplemental to the Preliminary Amendment filed August 1, 2001, and prior to examining the above-identified application, please amend the application as follows.

IN THE SPECIFICATION:

Please amend the specification as follows:

Page 1, before line 3, delete

"This application is a 371 of PCT/AU00/00056 filed February 2, 2001.",

and insert therefor

-- This application is a 371 of PCT/AU00/00056 filed February 2, 2000. --

REMARKS


The specification has been amended to correct an obvious typographical error therein. Hence, the amendment to the

SUPPLEMENTAL PRELIMINARY AMENDMENT
U.S. Appln. No. 09/890,463

specification does not constitute new matter, and thus entry is respectfully requested.

The Examiner is invited to contact the undersigned at his Washington telephone number on any questions which might arise.

Respectfully submitted,



Gordon Kit
Registration No. 30,764

SUGHRUE, MION, ZINN,
MACPEAK & SEAS, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3202
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

Date: August 27, 2001

A P P E N D I X

Marked-Up Version of Changes

IN THE SPECIFICATION:

The specification is amended as follows:

Page 1, before line 3, has been changed as follows:

This application is a 371 of PCT/AU00/00056 filed
[February 2, 2001] February 2, 2000.

JC17 Rec'd PCT/PTO 0 1 AUG 2001

09/890463

PATENT APPLICATION

#3/a

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ove HOECH-GULDBERG et al

CHAPT II filing

Appln. No.: of PCT/AU00/00056

Group Art Unit: 0000

Filed: August 1, 2001

Examiner: Unknown

For: PIGMENT PROTEIN FROM CORAL TISSUE

PRELIMINARY AMENDMENT

Assistant Commissioner
of Patents
Washington, D.C. 20231

Sir:

Prior to examining the above-identified application, please amend the application as follows.

IN THE SPECIFICATION:

Please amend the specification as follows:

Page 1, before line 3, insert

-- This application is a 371 of PCT/AU00/00056 filed February 2, 2001. --

IN THE CLAIMS:

Please cancel Claim 27.

Please amend the claims as follows:

Claim 1. (Amended) An isolated polynucleotide molecule comprising a nucleotide sequence encoding a pigment protein from coral tissue (PPCT) capable of emitting fluorescence upon irradiation by incident light, wherein maximal absorbance of

PRELIMINARY AMENDMENT
CHAPT II of PCT/AU00/00056

said incident light by said PPCT is in the range of 320-600 nm, and maximal fluorescence emission by said PPCT is in the range 300-700 nm.

Claim 2. (Amended) The isolated polynucleotide molecule of claim 1, wherein said PPCT has a maximal absorbance of said incident light in the range of 550-580 nm, and a maximal fluorescence emission in the range of 400-630 nm.

Claim 3. (Amended) An isolated polynucleotide molecule comprising a nucleotide sequence encoding a pigment protein from coral tissue (PPCT), wherein said polynucleotide molecule comprises a nucleotide sequence encoding a protein having the N-terminal amino acid sequence:

SVIAK (SEQ ID NO:1).

Claim 4. (Amended) An isolated polynucleotide molecule comprising a nucleotide sequence encoding a pigment protein from coral tissue (PPCT), wherein said polynucleotide molecule comprises a nucleotide sequence encoding a protein having the N-terminal amino acid sequence:

SVIAKQMTYKVYMSGTV (SEQ ID NO:2).

Claim 5. (Amended) The isolated polynucleotide molecule of claim 1, 2, 3 or 4, wherein said PPCT comprises a chromatophore region comprising the amino acid sequence: QYG.

Claim 6. (Amended) The isolated polynucleotide molecule of claim 5, wherein said polynucleotide molecule comprises a nucleotide sequence encoding a protein having an amino acid sequence corresponding to the sequence shown as SEQ ID NO:3 or 4.

PRELIMINARY AMENDMENT
CHAPT II of PCT/AU00/00056

Claim 7. (Amended) The isolated polynucleotide molecule of claim 5, wherein said polynucleotide molecule comprises a nucleotide sequence which has at least 80% identity to the sequence shown as SEQ ID NO:5 or 6.

Claim 8. (Amended) The isolated polynucleotide molecule of claim 7, wherein said polynucleotide molecule comprises a nucleotide sequence which has at least 90% identity to the sequence shown as SEQ ID NO:5 or 6.

Claim 9. (Amended) The isolated polynucleotide molecule of claim 7, wherein said polynucleotide molecule comprises a nucleotide sequence which has at least 95% identity to the sequence shown as SEQ ID NO:5 or 6.

Claim 10. (Amended) The isolated polynucleotide molecule of claim 7, wherein said polynucleotide molecule comprises a nucleotide sequence substantially corresponding to the sequence shown as SEQ ID NO:5 or 6.

Claim 11. (Amended) A substantially pure protein comprising the N-terminal amino acid sequence:

SVIAK (SEQ ID NO: 1).

Claim 12. (Amended) A substantially pure protein comprising the N-terminal amino acid sequence:

SVIAKQMTYKVYMSGTVN (SEQ ID NO:2).

Claim 14. (Amended) The protein of claim 13, wherein said protein can be purified from coral tissue from a coral family selected from the group consisting of: *Pocilloporidae*, *Acroporidae*, *Poritidae*, *Faviidae*, *Merulinidae* and *Fungiidae*.

Claim 17. (Amended) A vector comprising a polynucleotide molecule of claim 1, 2, 3 or 4.

PRELIMINARY AMENDMENT
CHAPT II of PCT/AU00/00056

Claim 19. (Amended) A process for producing the protein of claim 11 or 12, wherein the process comprises the step of cultivating a host cell transfected or transformed with a vector according to claim 17 under conditions suitable for expression of the polynucleotide molecule encoding the protein, and optionally recovering the expressed protein.

Claim 22. (Amended) An oligonucleotide probe or primer comprising a nucleotide sequence that hybridizes selectively to a polynucleotide molecule according to claim 1, 2, 3 or 4.

Claim 26. (Amended) The oligonucleotide probe or primer of claim 22, wherein the oligonucleotide probe or primer is conjugated to a detectable label.

Claim 28. (Amended) A sunscreen formulation comprising an effective amount of a protein according to claim 11 or 12, in admixture with a suitable pharmaceutical acceptable carrier or excipient.

Claim 29. (Amended) A filter for screening UV or other wavelength(s) of incident light comprising an effective amount of a protein according to claim 11 or 12.

IN THE ABSTRACT:

Please insert the Abstract attached hereto.

REMARKS


The specification has been amended to insert formal. Claim 27 has been cancelled. The remaining claims have been amended and an Abstract has been added in order to make the application consistent with U.S. patent practice. Hence, the

PRELIMINARY AMENDMENT
CHAPT II of PCT/AU00/00056

amendment to the specification, the cancellation of Claim 27 and the amendments to the additional claims do not constitute new matter.

The Examiner is invited to contact the undersigned at his Washington telephone number on any questions which might arise.

Respectfully submitted,



Gordon Kit

Registration No. 30,764

SUGHRUE, MION, ZINN,
MACPEAK & SEAS, PLLC
2100 Pennsylvania Avenue, N.W.
Washington, D.C. 20037-3202
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

Date: August 1, 2001

A P P E N D I X

Marked-Up Version of Changes

IN THE SPECIFICATION:

The specification is amended as follows:

Page 1, before line 3, the following has been inserted

This application is a 371 of PCT/AU00/00056 filed February 2, 2001.

IN THE CLAIMS:

Claim 27 has been cancelled.

The claims have been amended as follows:

Claim 1. (Amended) An isolated polynucleotide molecule comprising a nucleotide sequence encoding a pigment protein from coral tissue (PPCT) capable of emitting fluorescence upon irradiation by incident light, wherein maximal absorbance of said incident light by said PPCT is in the range of 320-600 nm, and maximal fluorescence emission by said PPCT is in the range 300-700 nm.

Claim 2. (Amended) The isolated polynucleotide molecule of claim 1, wherein [the encoded pigment protein] said PPCT has a maximal absorbance of said incident light in the range of 550-580 nm, and a maximal fluorescence emission in the range of 400-630 nm[]].

Claim 3. (Amended) An isolated polynucleotide molecule comprising a nucleotide sequence encoding a pigment protein from coral tissue (PPCT), wherein said polynucleotide molecule comprises a nucleotide sequence encoding a protein having the N-terminal amino acid sequence:

SVIAK (SEQ ID NO:1).

Claim 4. (Amended) An isolated polynucleotide molecule comprising a nucleotide sequence encoding a pigment protein from coral tissue (PPCT), wherein said polynucleotide molecule comprises a nucleotide sequence encoding a protein having the N-terminal amino acid sequence:

SVIAKQMTYKVYMSGTV (SEQ ID NO:2).

Claim 5. (Amended) The isolated polynucleotide molecule of [any one of the preceding claims] claim 1, 2, 3 or 4, wherein [the encoded protein includes] said PPCT comprises a chromatophore region comprising the amino acid sequence: QYG.

Claim 6. (Amended) The isolated polynucleotide molecule of [any one of the preceding claims] claim 5, wherein said polynucleotide molecule comprises a nucleotide sequence encoding a protein having an amino acid sequence corresponding to the sequence shown as SEQ ID NO:3 or 4.

Claim 7. (Amended) The isolated polynucleotide molecule of [any one of the preceding claims] claim 5, wherein said polynucleotide molecule comprises a nucleotide sequence which has at least 80% identity to the sequence shown as SEQ ID NO:5 or 6.

Claim 8. (Amended) The isolated polynucleotide molecule of claim 7, wherein said polynucleotide molecule comprises a nucleotide sequence which has at least 90% identity to the sequence shown as SEQ ID NO:5 or 6.

Claim 9. (Amended) The isolated polynucleotide molecule of claim 7, wherein said polynucleotide molecule comprises a nucleotide sequence which has at least 95% identity to the sequence shown as SEQ ID NO:5 or 6.

Claim 10. (Amended) The isolated polynucleotide molecule of [any one of the preceding claims] claim 7, wherein said polynucleotide molecule comprises a nucleotide sequence substantially corresponding to the sequence shown as SEQ ID NO:5 or 6.

Claim 11. (Amended) A substantially pure protein comprising the N-terminal amino acid sequence:

SVIAK (SEQ ID NO: 1)

[,said protein being in a substantially purified form].

Claim 12. (Amended) A substantially pure protein comprising the N-terminal amino acid sequence:

SVIAKQMTYKVYMSGTVN (SEQ ID NO:2)

[, said protein being in a substantially purified form].

Claim 14. (Amended) The protein of [any one of claims 11 to 13] claim 13, wherein said protein can be purified from coral tissue from a coral family selected from the group consisting of: *Pocilloporidae*, *Acroporidae*, *Poritidae*, *Faviidae*, *Merulinidae* and *Fungiidae*.

Claim 17. (Amended) A vector comprising a polynucleotide molecule [according to any one] of [claims 1 to 10] claim 1, 2, 3 or 4.

Claim 19. (Amended) A process for producing the protein of [any one of claims] claim 11 [to 16] or 12, wherein the process comprises the step of cultivating a host cell transfected or transformed with a vector according to claim 17 under conditions suitable for expression of the polynucleotide molecule encoding the protein, and optionally recovering the expressed protein.

Claim 22. (Amended) An oligonucleotide probe or primer comprising a nucleotide sequence that [hybridises] hybridizes selectively to a polynucleotide molecule according to [any one

of claims] claim [1 to 10] 1, 2, 3 or 4.

Claim 26. (Amended) The oligonucleotide probe or primer of [any one of claims] claim 22 [to 25], wherein the oligonucleotide probe or primer is conjugated to a detectable label.

Claim 28. (Amended) A sunscreen formulation comprising an effective amount of a protein according to [any one of claims] claim 11 [to 16] or 12, in admixture with a suitable pharmaceutical acceptable carrier or excipient.

Claim 29. (Amended) A filter for screening UV or other wavelength(s) of incident light comprising an effective amount of a protein according to [any one of claims] claim 11 [to 16] or 12.

IN THE ABSTRACT:

A new Abstract has been inserted.

JC17 Rec'd PCT/PTO 01 AUG 2001

09/890463
PCT/AU00/00056

WO 00/46233

10/PRTS

1

PIGMENT PROTEIN FROM CORAL TISSUE**Field of the Invention:**

The present invention relates to pigment proteins derived from corals, and particularly polynucleotide molecules encoding the pigment proteins, and uses thereof.

Background to the Invention:

There are a number of pigmented and/or fluorescent molecules which have been isolated and characterised from natural sources. Examples include apoequorin, a single polypeptide chain isolated from the luminous jellyfish *Aequorea victoria*, green fluorescent protein (GFP) and renilla luciferase isolated from the Renilla (also called sea pansies) which belong to a class of coelenterates known as anthozoans.

The present applicant has purified pigment protein from various coral tissues (PPCT) and cloned genes encoding PPCT which have unique and useful properties.

Disclosure of the Invention:

In a first aspect, the invention provides an isolated polynucleotide molecule comprising a nucleotide sequence encoding a pigment protein from coral tissue (PPCT) capable of emitting fluorescence upon irradiation by incident light, wherein maximal absorbance of said incident light is in the range of 320 - 600 nm (preferably, 550 - 580 nm), and maximal fluorescence emission is in the range 350 - 700 nm (preferably, 400 - 650 nm).

Preferably, the isolated polynucleotide molecule comprises a nucleotide sequence encoding a protein having the N-terminal amino acid sequence:

SVIK (SEQ ID NO:1).

More preferably, the isolated polynucleotide molecule comprises a nucleotide sequence encoding a protein having the N-terminal amino acid sequence:

SVIKQMTYKVYMSGTV (SEQ ID NO: 2).

Still more preferably, the isolated polynucleotide molecule comprises a nucleotide sequence encoding a protein having an amino acid sequence corresponding to the sequence shown hereinafter as SEQ ID NO: 3 or 4.

WO 00/46233

PCT/AU00/00056

2

Even more preferably, the isolated polynucleotide molecule comprises a nucleotide sequence which has at least 80%, more preferably at least 90 % and most preferably at least 95%, identity to the sequence shown hereinafter as SEQ ID NO: 5 or 6.

5 Most preferably, the isolated polynucleotide molecule comprises a nucleotide sequence substantially corresponding to the sequence shown hereinafter as SEQ ID NO: 5 or 6.

10 In a preferred embodiment of the invention, the isolated polynucleotide molecule comprises a nucleotide sequence which is capable of hybridising to the sequence shown as SEQ ID NO: 5 or 6 under high stringency conditions, and is less than 5000 nucleotides in length, although it can be less than 1000 or even 500 nucleotides in length. However, preferably, hybridising polynucleotide molecules according to the invention are at least 18 nucleotides in length.

15 Polynucleotide molecules according to the invention which may hybridise to the sequence shown as SEQ ID NO: 5 or 6 under high stringency conditions, include polynucleotide molecules encoding PPCT isoforms known to the present applicant which are of 221 amino acids in length. Such polynucleotide molecules include a stop codon in place of the codon
20 encoding Cys²²¹ shown in SEQ ID NO: 5 or 6.

In a second aspect, the invention provides a protein comprising the N-terminal amino acid sequence:

SVIAK (SEQ ID NO:1), said protein being in a substantially purified form.

25 Preferably, the substantially purified protein comprises the N-terminal amino acid sequence:

SVIAKQMTYKVYMSGTV (SEQ ID NO: 2).

More preferably, the protein comprises an amino acid sequence substantially corresponding to the sequences shown hereinafter as SEQ ID
30 NO 3 or 4.

The protein according to the present invention (PPCT) has the following characteristics:

- i) Aqueous soluble protein (231-235 amino acids in length);
- ii) Absorbance spectra with λ_{\max} ranging from 340-600 nm;
- 35 iii) Light induced;
- iv) Mostly in the form of a dimer, though sometimes trimeric;

WO 00/46233

PCT/AU00/00056

3

- v) About 22% amino acid identity and about 56% amino acid similarity with green fluorescent protein (GFP);
- vi) Amino acid sequence "QYG" in PPCT instead of "SYG" in GFP chromatophore position;
- 5 vii) Estimated PI = 9.5; and
- viii) Synthesised at high temperatures (e.g. 35°C) and stable at higher temperatures (e.g. 40°C).

PPCTs which absorb maximally at 560 - 600 nm are weakly fluorescent (excitation at 560 - 600 nm with emission at 600 - 650 nm) under all
10 conditions. Other PPCTs absorb/excite and emit at different wavelengths. Roughly, there are four classes: Fluorescent behaviours sort PPCTs into those that fluoresce when excited at wavelengths of 300 - 360 nm, 420 - 465 nm, 480 - 490 nm and 550 - 600 nm. These molecules have emission maxima at 400 - 450 nm, 480 - 490 nm, 500 - 505 nm and 610 - 630 nm, respectively
15 (see Table 4).

PPCT can be purified from the tissues of the following coral families: Pocilloporidae, Acroporidae, Poritidae, Faviidae, Merulinidae, Fungiidae.

Preferably, PPCT is purified from the tissue of the coral: *Acropora aspera*, *Acropora digitifera*, *Acropora horrida*, *Acropora formosa*, *Montipora monasteriata*, *Montipora caliculata*, *Pocillopora damicornis*, *Porites murrayensis*, *Porites lobata*, *Plesiastrea versipora* or *Seriatopora hystrix*.
20

More preferably, PPCT is purified from the tissue of the coral: *Acropora aspera*, *Acropora horrida*, *Montipora monasteriata*, *Montipora caliculata*, *Porites murrayensis*, *Porites lobata*, or *Plesiastrea versipora*.
25

Alternatively, PPCT can be purified from a culture of a recombinant host cell expressing PPCT from an introduced PPCT-encoding polynucleotide molecule.
30

In a third aspect, the invention provides a suitable vector for the replication and/or expression of a polynucleotide molecule according to the first aspect of the present invention.
35

The vector may be, for example, a plasmid, virus or phage vector provided with an origin of replication, and preferably a promoter for the expression of the polynucleotide and, optionally, a regulator of the promoter. The vector may contain one or more selectable markers, for example an ampicillin resistance gene in the case of a bacterial plasmid or a neomycin resistance gene for a mammalian expression vector. The vector may be used

WO 00/46233

PCT/AU00/00056

4

in vitro for, for example, the production of RNA or, alternatively, for the transfection or transformation of a host cell.

A fourth aspect of the invention provides host cells transfected or transformed with the vector of the third aspect of the present invention.

Suitable host cells for cloning or expressing PPCT are prokaryote, yeast, or higher eukaryote cells.

Suitable prokaryotes include eubacteria, such as Gram-negative or Gram-positive organisms, for example, *E. coli*, *Bacilli* such as *B. subtilis* or *B. thuringiensis*, *Pseudomonas* species such as *P. aeruginosa*, *Salmonella typhimurium* or *Serratia marcescens*.

Eukaryotic microbes such as filamentous fungi or yeast are also suitable hosts for expressing PPCT. *Saccharomyces cerevisiae*, or common baker's yeast, is the most commonly used among lower eukaryotic host microorganisms. However, a number of other genera, species, and strains are commonly available and useful herein, such as *Schizosaccharomyces pombe*; *Kluyveromyces* hosts such as *K. lactis*; filamentous fungi such as *Neurospora* or *Penicillium*; and *Aspergillus* hosts such as *A. nidulans* and *A. niger*.

Suitable higher eukaryotic host cells can be cultured vertebrate, invertebrate or plant cells. Insect host cells from species such as *Spodoptera frugiperda*, *Aedes aegypti*, *Aedes albopictus*, *Drosophila melanogaster*, and *Bombyx mori* can be used. Plant cell cultures of cotton, corn, potato, soybean, tomato and tobacco can be utilised as hosts. Typically, plant cells are transfected by incubation with certain strains of the bacterium *Agrobacterium tumefaciens*.

Propagation of vertebrate cells in culture (tissue culture) has become a routine procedure in recent years. Examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7, ATCC CRL 1651); human embryonic kidney line (293 or 293 cells subcloned for growth in suspension culture); baby hamster kidney cells (BHK, ATCC CCL 10); Chinese hamster ovary cells/-DHFR (CHO); mouse sertoli cells, monkey kidney cells (CV1, ATCC CCL 70); human cervical carcinoma cells (HELA, ATCC CCL 2); canine kidney cells (MDCK, ATCC CCL 34), and a human hepatoma cell line (Hep G2). Preferred host cells are human embryonic kidney 293 and Chinese hamster ovary cells.

Host cells are transfected or, more preferably, transformed, with expression or cloning vectors of the invention and cultured in conventional

WO 00/46233

PCT/AU00/00056

5

nutrient media modified as appropriate for inducing promoters, selecting transformants, or amplifying the genes encoding the desired sequences. Transformation means introducing DNA into an organism so that the DNA is replicable, either as an extrachromosomal element or by chromosomal integration. Depending on the host cell used, transformation is carried out using standard techniques appropriate to such cells.

In a fifth aspect, the invention provides a process for producing a protein according to the second aspect of the present invention, the process comprises that step of cultivating a host cell transfected or transformed with an (expression) vector of the third aspect of the present invention under conditions suitable for expression of the polynucleotide molecule encoding the protein, and optionally recovering the expressed protein.

Such cells can be used for the production of commercially useful quantities of the encoded protein.

Since PPCT's appear to exhibit stability at high temperatures (e.g. 35 - 40°C), the process of the fifth aspect may be performed at or near optimal cultivating temperatures (e.g. 30 - 37°C).

In a sixth aspect, the invention provides an oligonucleotide probe or primer, the probe or primer having a sequence that hybridises selectively to a polynucleotide molecule according to the first aspect of the present invention.

In a preferred embodiment of the sixth aspect, the oligonucleotide probe or primer comprises at least 8 nucleotides, more preferably at least 18 nucleotides, and most preferably at least 25 nucleotides.

In a further preferred embodiment, the oligonucleotide probe or primer is used as a detectable probe wherein the oligonucleotide is conjugated with a label such as a radioisotope, an enzyme, biotin, a fluorescent molecule or a chemiluminescent molecule.

In a seventh aspect, the invention consists in the use of a protein according to the second aspect as a tissue marker, fluorescent marker or general dyestuff.

It is anticipated that the protein of the invention could be used as a harmless protein-based marker for following gene expression in transformed tissues. The protein of the invention also has potential as a readily manufactured, harmless dyestuff.

WO 00/46233

PCT/AU00/00056

6

In an eighth aspect, the invention provides a sunscreen formulation comprising an effective amount of a protein according to the second aspect, in admixture with a suitable pharmaceutical acceptable carrier or excipient.

In a ninth aspect, the invention provides a filter for screening UV or other wavelength(s) of incident light comprising an effective amount of a protein according to the second aspect.

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

Throughout this specification, where reference is made to percentage levels of nucleotide sequence identity, those levels are as calculated by the BLAST program blastn as described by Altschul, S.F. et al., "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Research, Vol. 25, No. 17, pp 3389-3402 (1997).

As used herein, the term "high stringency conditions" refers to conditions that (1) employ low ionic strength and high temperature for washing, for example, 15 mM NaCl/1.5 mM sodium citrate/0.1% NaDodSO₄ at 50°C; (2) employ during hybridisation a denaturing agent such as formamide, for example, 50% (vol/vol) formamide with 0.1% bovine serum albumin, 0.1% Ficoll, 0.1% polyvinylpyrrolidone, 50 mM sodium phosphate buffer at pH 6.5 with 750 mM NaCl, 75 mM sodium citrate at 42°C; or (3) employ 50% formamide, 5 x SSC (750 mM NaCl, 75 mM sodium citrate), 50 mM sodium phosphate (pH 6.8), 0.1% sodium pyrophosphate, 5 x Denhardt's solution, sonicated salmon sperm DNA (50 µg/ml), 0.1% SDS and 10% dextran sulfate at 42°C in 0.2 x SSC (30 mM NaCl, 3 mM sodium citrate) and 0.1% SDS.

The term "substantially corresponding" as used herein in relation to nucleotide sequences is intended to encompass minor variations in the nucleotide sequence which due to degeneracy in the DNA code do not result in a change in the encoded protein. Further, this term is intended to encompass other minor variations in the sequence which may be required to enhance expression in a particular system but in which the variations do not result in a change in the functional characteristics of the encoded protein.

WO 00/46233

PCT/AU00/00056

7

The term "substantially corresponding" as used herein in relation to amino acid sequences is intended to encompass minor variations in the amino acid sequences which do not result in a change in the functional characteristics of PPCT. These variations may include conservative amino acid substitutions. The substitutions envisaged are:-

G, A, V, I, L, M; D, E, N, Q; S, T; K, R, H; F, Y, W, H; and P, N α -alkylamino acids.

In order that the present invention may be more clearly understood, preferred forms will be described with reference to the following examples and drawings.

Brief description of the accompanying figures:

Figure 1 shows a nucleotide sequence of a degenerative primer useful for hybridising to genes encoding PPCT.

Figures 2 provides an electroblot of SDS PAGE of gel filtration HPLC fractions collected for sequencing. The lanes are as follows: 1. *A. horrida*, 2. *M. caliculata*, 3. *M. monasteriata*, 4. *P. lobata*, 5. *P. murrayensis*, 6. *A. formosa*, 7. *S. hystrix*, 8. *P. damicornis*, 9. *S. pistillata*. Molecular weight markers are shown in the unmarked lanes.

Figure 3 shows a amino acid sequence encoded by clone T7SP6BASPOC3 of Figure 3.

Figure 4 shows a amino acid sequence encoded by clone T7SP6BASPOC4 of Figure 4.

Figure 5 shows a cDNA nucleotide sequence of clone T7SP6BASPOC3 encoding PPCT from *A. aspera*.

Figure 6 shows a cDNA nucleotide sequence of clone T7SP6BASPOC4 encoding PPCT from *A. aspera*.

Figure 7 shows a vector suitable for introduction and subsequent bacterial expression of cDNA encoding PPCT.

Figure 8 provides a schematic diagram of molecular models of the principal pigment polypeptide from reef-building corals. A. MOLSCRIPT cartoon, from N-terminus to C-terminus. Arrows represent β -strands and spirals indicate helical segments. heavy atoms of the fluorophore (Q61, Y62 and G63) are shown in ball-and-stick representation. B. Charged, polar and hydrophobic side chains in the immediate vicinity are shown in ball-and-stick representation.

WO 00/46233

PCT/AU00/00056

8

Figure 9 shows the absorbance, excitation and emission spectra of GFP-like pigments (pocilloporin) from A-C. *Acropora aspera* and D-F. *Pocillopora damicornis*. Samples taken at 27-28 min (A. and D.) and 25-26 min (B. and E.) into gel filtration run showing dominant fluorescent excitation (1-3, 5-6) and emission (1-3, 5-6) spectra. Composite absorbance (4, 7, peaks at 580 and 560 nm) and emission spectra (dashed lines) are shown in panels C. and F.

Figure 10 shows the interaction between PPCTs and the Peridinin-chlorophyll-protein (PCP) complex of symbiotic dinoflagellates. Line 1 indicates the excitation spectra of the PCP complex of symbiotic dinoflagellates (*Acropora aspera*), which results in fluorescence emission by the isolated PCP complex at 674 nm (line 2, equivalent to the Q_y Chlorophyll a transition). Lines 3, 4, 5 and 6 indicate typical excitation spectra of GFP-like pocilloporins in the reef-building corals *Acropora aspera* and *Pocillopora damicornis*. Corresponding arrows indicate where emission maxima occur. Note the coupling of the emission (arrows) and excitation wavelengths of successive fluorescent pigments. Dotted lines indicate respective excitation peaks for the PCP complex and approximate position of the Q_x band of Chlorophyll a . A = Chlorophyll a (441 nm), B = Peridinin (472 nm) and C = Additional vibrational band of Peridinin (525 nm).

Example 1:

General Molecular Biology

Unless otherwise indicated, the recombinant DNA techniques utilised in the present invention are standard procedures, well known to those skilled in the art. Such techniques are described and explained throughout the literature in sources such as, J. Perbal, A Practical Guide to Molecular Cloning, John Wiley and Sons (1984), J. Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbour Laboratory Press (1989), T.A. Brown (editor), Essential Molecular Biology: A Practical Approach, Volumes 1 and 2, IRL Press (1991), D.M. Glover and B.D. Hames (editors), DNA Cloning: A Practical Approach, Volumes 1-4, IRL Press (1995 and 1996), and F.M. Ausubel et al. (Editors), Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience (1988, including all updates until present) and are incorporated herein by reference.

WO 00/46233

PCT/AU00/00056

9

Gene/DNA Isolation

The DNA encoding a protein may be obtained from any cDNA library prepared from tissue believed to express the gene mRNA and to express it at a detectable level. DNA can also be obtained from a genomic library.

Libraries are screened with probes or analytical tools designed to identify the gene of interest or the protein encoded by it. For cDNA expression libraries, suitable probes include monoclonal or polyclonal antibodies that recognise and specifically bind the protein; oligonucleotides of about 20-80 bases in length that encode known or suspected portions of cDNA from the same or different species; and/or complementary or homologous cDNAs or fragments thereof that encode the same or a hybridising gene. Appropriate probes for screening genomic DNA libraries include, but are not limited to, oligonucleotides; cDNAs or fragments thereof that encode the same or hybridising DNA including expressed sequence tags and the like; and/or homologous genomic DNAs or fragments thereof. Screening the cDNA or genomic library with the selected probe may be conducted using standard procedures as described in chapters 10-12 of Sambrook *et al.*

An alternative means to isolate a gene encoding is to use polymerase chain reaction (PCR) methodology as described in section 14 of Sambrook *et al.* This method requires the use of oligonucleotide probes that will hybridise to the gene.

The oligonucleotide sequences selected as probes should be of sufficient length and sufficiently unambiguous that false positives are minimised. The actual nucleotide sequence(s) is usually based on conserved or highly homologous nucleotide sequences or regions of the gene. The oligonucleotides may be degenerate at one or more positions. The use of degenerate oligonucleotides may be of particular importance where a library is screened from a species in which preferential codon usage in that species is known. The oligonucleotide must be labelled such that it can be detected upon hybridisation to DNA in the library being screened. The preferred method of labelling is to use ³²P-labelled ATP with polynucleotide kinase, as is well known in the art, to radiolabel the oligonucleotide. However, other methods may be used to label the oligonucleotide, including, but not limited to, biotinylation or enzyme labelling.

WO 00/46233

PCT/AU00/00056

10

Nucleic acid having all the protein coding sequence is obtained by screening selected cDNA or genomic libraries, and if necessary, using conventional primer extension procedures as described in section 7.79 of Sambrook *et al.*, to detect precursors and processing intermediates of mRNA that may not have been reverse-transcribed into cDNA.

Another alternative method for obtaining the gene of interest is to chemically synthesise it using one of the methods described in Fingels *et al.* (Agnew Chem. Int. Ed. Engl. 28: 716-734, 1989). These methods include triester, phosphite, phosphoramidite and H-Phosphonate methods, PCR and other autoprimer methods, and oligonucleotide syntheses on solid supports. These methods may be used if the entire nucleic acid sequence of the gene is known, or the sequence of the nucleic acid complementary to the coding strand is available, or alternatively, if the target amino acid sequence is known, one may infer potential nucleic acid sequences using known and preferred coding residues for each amino acid residue.

Purification Scheme

- (i) Extraction of coloured pigment from coral tissue by immersing coral overnight at 4°C in 0.6 M Potassium Phosphate buffer pH 6.65.
- (ii) Gel filtration (Pharmacia, Superose HR 10/30) monitored at 280 nm & λ_{max} eluting with Phosphate buffer (peak collection)
- (iii) Desalt and lyophilise
- (iv) Separate on 15% SDS-PAGE
- (v) Electroblot onto PVDF using CAPS buffer
- (vi) N-terminal Sequence analysis (Australian National University Sequencing Facility)

cDNA Library

Species: Blue tipped *Acropora aspera*

- (i) Isolation of mRNA: Qiagen mRNA Kit (poly A+) or, more preferably, by the method described by Chomczynski and Sacchi (Anal. Biochem. 162, 156-159 (1987)).
- (ii) cDNA made with SMART PCR cDNA Synthesis Kit from CLONTECH
- (iii) cDNA ligated into Stratagene LambdaZapII EcoR1 cut/CIAP and packaged by Stratagene Gigapack II.

PCR out of Library

- (i) Using gel purified oligomer as 5' primers and SMART PCR adaptor 3' primers - PCR amplified genes

WO 00/46233

PCT/AU00/00056

11

(ii) Gel purified product ligated into pGemT easy vector (Promega) LICOR sequencing from T7 and SP6 primers and translated sequence to give the amino acid sequence.

Production of Mutants

It is anticipated that the fluorescence properties of PPCTs which are weakly fluorescent may be improved by mutagenesis. Such mutants (and the polynucleotide molecules encoding them) are to be considered as part of the present invention.

The sites for mutation can be modified individually or in series, for example by:

- (i) substituting a target residue first with conservative amino acid choices and then with more radical selections depending upon the result to be achieved,
- (ii) deleting a target residue, and/or
- (iii) inserting residues or other ligands adjacent to the target residue.

One useful method for identification of residues or regions for mutagenesis is called "alanine scanning mutagenesis" as described by Cunningham and Wells (*Science* (1989) 244: 1081-1085). Here, a target residue or group of target residues are identified (e.g. charged residues such as Arg, Asp, His, Lys and Glu) and substituted by a neutral or negatively charged amino acid (most preferably, Ala or poly-Ala) to affect the interaction of the amino acids with the surrounding aqueous environment in or outside the cell. Those domains demonstrating functional sensitivity to the substitutions then are refined by introducing further or other mutations. Thus, while the site for introducing an amino acid sequence mutation is predetermined, the nature of the mutation *per se* need not be predetermined. For example, to optimise the performance of a mutation at a given site, alanine scanning or random mutagenesis may be conducted at the target codon or region and the expressed mutants are screened for the optimal combination of desired function.

Example 2:

METHODS

Isolation and purification of pigment proteins

Pigment proteins were purified and electrophoresed under denaturing conditions using the method described in Dove et al., *Biol Bull*, 189, 288-297,

WO 00/46233

PCT/AU00/00056

12

1995. The resulting SDS-PAGE subunits were transferred onto PVDF paper in the presence of CAPS buffer. The 28 kD subunits isolated from five species of hermatypic corals were then sequenced by the Biomolecular Resource Facility at the Australian National University.

5 **RNA isolation - cDNA library construction - thermocycler conditions**

Branch tips (blue) of *Acropora aspera* were collected at noon on November 24 1997 from the Heron Island reef flat and taken immediately to the research station. The total RNA from 10 tips (approximately 1 cm long) were isolated immediately and a cDNA library was made using a SMART
10 PCR cDNA Synthesis Kit from Clontech Laboratories (Palo Alto, CA, USA). Full length mRNA sequences of PPCT were amplified out of the library using gel purified degenerative primers made to the first 10 amino acids at the 5' end or N-terminus of the most common sequence (Table 1) and SMART PCR CDS 3' primers. This yielded a single product that was approximately 760 bp
15 in length. Gel purified product was ligated into pGemT easy vector (Promega, Madison, WI, USA) and sequenced using T7 and SP6 primers (2 clones, forward and reverse directions, LICOR, USA). The resultant derived proteins had 231 amino acids (POC3) and 235 amino acids (POC4) with only a few functionally similar amino acid substitutions.

20 **Model construction**

Sequence alignment was carried out using MALIGN (Johnson et al. 1993) with the default scoring matrix derived from multiple-structure alignments and visually edited to optimise the alignment of conserved and chemically similar residues. The program MODELLER was used to generate
25 the POC4 model, based on the template structure of the green fluorescent protein (PDB 1GFL). The initial model was iteratively refined by in-built molecular dynamics with simulated annealing protocols, to improve the structural quality as computed by PROCHECK. GRASP was used to build the molecular surface of the protein model.

30 **Measurement of Emission and Excitation spectra**

The following gel filtration fractions were analysed for excitation and emission spectra: (i) Gel filtration fractions at intervals of one minute were collected between 25 min and 29 min that correspond approximately to trimeric through monomeric proteins of subunits ranging between 25 kD and
35 29 kD, (ii) Narrow gel filtration fractions collected around the wavelength of maximal absorbance for protein purification, these ranged from

WO 00/46233

PCT/AU00/00056

13

approximately 26 min through approximately 28 minutes depending on coral species (Table 1).

Isolation of the peridinin-chlorophyll-protein (PCP complex from zooxanthellae. The water soluble peridinin-chlorophyll-protein (PCP) complex was isolated from zooxanthellae isolated from several corals (*Montipora digitata*, *Acropora aspera*) by homogenizing tissue removed from corals by using an air-brush. A symbiotic dinoflagellate rich fraction was created by spinning the homogenate at 3000 rpm for 2 min. The pellet was incubated with ice-cold phosphate buffer. PCP complexes were further purified and electrophoresed under denaturing conditions using the method described in Dove et al 1995 *supra* except that fractions were collected between 30-31 min.

RESULTS AND DISCUSSION

PPCT from ten species of reef-building corals were isolated. The isolated proteins had native molecular weights (approximate) that ranged from 42 to 69 kD (Table 1) and consisted of subunits that were approximately 28 kD in size (Figure 2). The N-termini of subunits from 6 species of Acroporid and Poritid corals were sequenced. Although there were a number of background sequences in the 28 kD band, the sequence beginning with the amino acids SVIAK was common to all families (Table 1). Ion exchange chromatography using a Mono-Q column (Pharmacia, Sweden) and a variety of pH gradients and salt concentrations failed to give further resolution of the gel filtration fraction. This suggests that the surface charges on these polypeptides are very similar. In order to derive the complete sequence of the polypeptide with the common N-terminal sequence, cDNA libraries were constructed from a blue pigmented coral, *Acropora aspera*. This resulted in the successful amplification of the full length mRNA coding this protein. Amplification resulted in two clones with a few nucleic acid differences, yielding proteins of length 231 (POC3) (see Figure 5) and 235 (POC4) (see Figure 6), both having isoforms with stop codons at amino acid 221. Database searching matched these sequences with Green Fluorescent Protein (GFP) from the jellyfish *Aequorea victoria* (Cl. Scyphozoa). Significantly, GFP is also a dimer with a 28 kd subunit (Tsien, *Ann. Rev. Biochem.*, 67, 509-544, 1998). The alignment of POC4 with GFP and the GFP-like proteins isolated from *Discosoma* sp. (Order Corallomorpharia, Cl. Anthozoa, Matz et al., *Nature Biotech.* 17, 969-973, 1999) showed 19.6% identity with

WO 00/46233

PCT/AU00/00056

14

GFP and 65.3% identity with drFP583 (Table 2). When concentrated, the narrow gel filtration fractions have approximately the same coloration as the coral from which they were derived (i.e. blue, purple or pink). The pigments observed in corals under visible light are therefore due to this family of GFP-proteins. A dimer with a 28 kD subunit matches the profile of GFP.

The construction of a 3-dimensional model revealed that the PPCT sequence can adopt the 'β-can' structure of green fluorescent protein (PDB 1GFL) (Yang et al., Nature Biotech, 14, 1246-1251, 1996), with 11 β-strands and a chromophore (composed of the modified residues Gln-61, Tyr-62 and Gly-63) within the protein (Figure 8B). The model shows that the chromophore is formed by the "QYG" amino acid motif. The absence of part of the N-terminal cap (see alignment in Table 2, Figure 8A,B) in the PPCT suggests that this molecule may have a reduced ability to fluoresce as this region was found to be crucial for GFP in N-terminal truncation experiments. It is suspected that this sequence represents the high absorbance-low emission form of the pigment discussed below (excitation maxima at 570 nm, Figure 9). The GRASP molecular surface of the PPCT model (not shown) reveals no channels, suggesting that the fluorophore is well protected from solvent. The immediate vicinity of the fluorophore appears completely shielded from bulk solvent, with 26 residues within 5 Å (listed in Table 4 and shown in Figure 8A,B) as compared to 19 residues in GFP. This increase is partially attributable to the hydrogen bonds formed by the side chain of Gln-61. Two resonance forms have been proposed for the fluorophore, one with a partial negative charge either on the benzyl oxygen (OH) of Tyr-62 and the other with a negative charge on the carbonyl oxygen of Tyr-62 (part of the imidazolidone ring). Both resonance forms appear equally stabilized by Arg-192 and Arg-90 (Table 4, in bold), respectively and it is thus not possible to speculate on which form is dominant from the model. Yang et al. (1996) *supra* have suggested that mutation of Thr-203, Glu-222 or Ile-167 of GFP would directly affect the fluorophore, from steric and electrostatic considerations. The corresponding residues in PPCT, Arg-192, Glu-210 and Met-158, are all located in the vicinity of the fluorophore, suggesting that these are critical residues for the function of the protein. Of special importance is the presence of tryptophan residues within the "β-can" structure: Trp-88 (corresponding to Asn-94 of GFP), within van der Waals contact of the fluorophore, with Trp-53 and Trp-138 (10.8 Å and 6.7 Å,

WO 00/46233

PCT/AU00/00056

15

respectively) from the fluorophore. The latter, aligning with Trp-57 (13 Å in WT; Yang et al. (1996) *supra*) and Tyr-145 of GFP, possibly contribute to charge delocalization. It is suggested that these tryptophans are important in stabilizing and protecting the PPCT from ultraviolet radiation, which adds to its potential function under high levels of solar radiation (see below). The model structure also explains the unusual stability of PPCTs, that are expressed in shallow water environments that may exceed 35° C as opposed to GFP with a maximum at 25° C.

Examination of the fluorescence of native PPCT from ten species of reef-building corals revealed a broad range of fluorescent behaviour which was similar to that seen in both native and mutant GFPs (Tsien et al., Biochem., 67, 509-544, 1998). Fluorescence behaviours roughly sort molecules into those that fluoresce when excited at wavelengths of 300-360 nm, 420-465 nm, 480-490 nm and 550-600 nm (Table 4). These molecules had emission maxima at 400-450 nm, 480-490 nm, 500-505 nm and 610-630 nm respectively. The group of molecules that absorb in the 550-600 nm range and emit in the 610-630 nm range have very low intensity fluorescence as can be seen from the high absorbance reading in this range for narrow gel filtration fractions (and high protein content), and their comparatively low fluorescence (Figure 9). There were also quite substantial differences between species with respect to the types of PPCTs that were present in each coral species. PPCT derived from the blue branch tips of the Acroporid coral *Acropora aspera*, for example, fluoresced under both UVA and visible light and showed three distinct excitation maxima of 340 nm, 420 nm and 576 nm (Figure 9 A,B). Excitation at these wavelengths led to fluorescent emissions at 445 nm (blue), 490 nm (blue-green) and 630 nm (orange-red, weak) respectively. If HPLC samples were taken at 25-26 min into a run, PPCT with an excitation maximum of 340 nm dominated while PPCTs with excitation maxima of 420 nm and 576 nm dominated samples taken at 26-27 min. Several types of PPCT were found within the tissues of *Acropora aspera*, with some forms having a greater potential to form homo, possibly hetero, dimers or trimers than others. The different elution times were also seen with PPCTs from all other species. GFP and mutants have single (major, excluding shoulders) excitation and emission maxima, further strengthening the case that each pair of excitation and emission spectra found represent individual PPCTs.

WO 00/46233

PCT/AU00/00056

16

The bright colours of reef-building corals are consequently due to a combination of the absorptive and fluorescent properties of one or more GFP-like pocilloporins. For example, the blue colour of the branch tips of *Acropora aspera* is due to strong absorbance in the green to orange sections of visible spectra (peak absorbance = 580 nm, and no absorbance at wavelength longer than 650 nm) and substantial blue fluorescence emission (Figure 9C). In purple species, the absorbance maxima shift slightly away from the red end of the spectra (Table 3), but strong blue fluorescence at excitations of approximately 340 nm and/or 420-465 nm is retained. Pink coral species like *Pocillopora damicornis* (Figure 9F), on the other hand, have PPCTs that have peak absorbance at 560 nm and no absorbance beyond 600 nm. In this case, mostly yellow and red light is transmitted and reflected back by the underlying white coral skeleton and blue fluorescence arising from excitation at 358 nm or 484 nm is relatively weak or is non-existent. Many corals are highly fluorescent at 340 nm but either do not have any visible host colour under visible light or are a luminescent green. These corals probably have the 340 nm and 420-465 nm excitation variety of GFP-like protein (green emitters) and do not have the high absorbance-low emission blue or pink varieties of PPCT described here.

Green Fluorescent Protein was discovered in the bioluminescent jellyfish (Cl. Scyphozoa) *Aequorea victoria* where it has an excitation maximum at 400 nm (shoulder at 475 nm), and an emission peak at 509 nm. In this species, GFP acts to emit green light after absorbing the blue-green light originating from the Ca^{2+} activated photoprotein, aequorin (Morin et al., J. Cell Physiol., 77, 313-318). Reef-building corals are not bioluminescent. So, why do reef-building corals have fluorescent GFP-like proteins like PPCTs? The molecular properties of PPCT suggest that these proteins function in photoprotection and light harvesting as has been suggested by several authors. Different PPCTs appear to have different roles. The high absorbance-low emission varieties specifically absorb light from 550-600 nm at wavelengths which is too long for absorption by the PCP complex (410-550 nm, Figure 13) and emit at wavelengths too short for the Q_y band of chlorophylls *a* and *c*. The absorbance range of these low emitting PPCTs coincides with the Q_x bands of chlorophylls *a* and *c*. The Q_x band is poised to absorb scattered light due to the different dipole orientations of these chlorophylls. As the proportion of scattered light to total irradiance increases

WO 00/46233

PCT/AU00/00056

17

with light intensity, this particular PPCT is likely to act as a light-dependent screening pigment and reduce photoinhibition of the symbiotic dinoflagellates in high light habitats. The fact that the concentrations of the high absorbance-low emission PPCTs are correlated with PAR and not UV is further evidence of this role.

Other PPCTs convert UV radiation (down to at least 300 nm, Figure 9a) and blue light into longer wavelengths. This suggests two additional roles of PPCT under both high and low light conditions respectively. The UV component of solar radiation has been shown to have a major and negative effect on coral and their dinoflagellate symbionts. By converting UV radiation into blue light (440-445 nm) and then (in many cases) into blue-green light (480-490 nm and 500-505 nm), UV radiation can be converted into less harmful visible radiation that can be absorbed by the PCP complex of the symbiotic dinoflagellates (Figure 10). The PCP complex is a highly regulated light-harvesting complex that can either direct the captured energy toward the two photosystems or dump excess light energy as heat via transfers to associated carotenoids. It is striking how some of these proteins direct energy away from the Soret band at about 430 nm and into a trough in the absorbance wavelengths of the PCP complex (Figure 10). By doing this, they clearly have a role in limiting the direct entry of light into Chlorophyll *a* by converting some light into that that can be absorbed by other components of the PCP complex. The behaviour of some PPCTs in converting UV light to longer wavelengths also appears poised to play a role in low light habitats. By converting non-photosynthetic UV light into blue and green light, PPCT extends the range of wavelengths over which symbiont photosynthesis can occur. Consequently, in low light habitats, the 300-360 nm and 420-465 nm forms of PPCT can function as a host based accessory pigments that increase light availability for reef-building corals that grow there. The observation that fluorescent pigment granules enhance the photosynthetic rate of deepwater corals further supports this additional role of PPCT.

WO 00/46233

PCT/AU00/00056

18

Table 1. Size and N-terminus amino acid sequences of subunits from HPLC gel filtration fractions.

| Coral Species | Elution time (min) | Approximate native molecular weight (Kd) | N-terminal amino acid sequences of resulting subunit (28 kD) |
|-------------------------------|--------------------|--|--|
| <i>Stylophora pistillata</i> | 27.9 | 42 | Nd |
| <i>Pocillopora damicornis</i> | 27.6 | 46 | Nd |
| <i>Seriatopora hystrix</i> | 26.9 | 57 | Nd |
| <i>Acropora digitifera</i> | 27.6 | 46 | Nd |
| <i>Acropora horrida</i> | 26.5 | 64 | SVIAKQMTYKVYMSGTV (SEQ ID NO: 2) |
| <i>Acropora formosa</i> | 26.5 | 64 | Nd |
| <i>Acropora aspera</i> | 26.4 | 65 | SVIAKQMTYKVYMSGTVN* (SEQ ID NO: 7) |
| <i>Montipora monasteriata</i> | 26.4 | 65 | SVIAK (SEQ ID NO: 1) |
| <i>Montipora caliculata</i> | 26.2 | 69 | SVIAKQMTYKVYMSGTVN (SEQ ID NO: 7) |
| <i>Porites murrayensis</i> | 26.3 | 67 | SVIAKQMTYKVYMSGTVN (SEQ ID NO: 7) |
| <i>Porites lobata</i> | 26.3 | 67 | SVIAKQMTYKVYMSGTVNNHYEFVT (SEQ ID NO: 8) |

5 Asterisk means sequence derived from cDNA

WO 00/46233

PCT/AU00/00056

19

Table 2. Nucleotide and amino acid sequence of mRNA encoding a GFP-like protein from the reef-building coral *Acropora aspera*.

| | | | | | | | | | | | | | | | | | | | | | | |
|-----------|---------|----------|----|----|---|------|-------|---|---|---|--------|------|---|-----|---|--------|----|---|----|-----|----|---|
| poc4 | SVTAQQT | KVYSTNGH | RE | EN | K | KPYE | E | T | R | T | TKGGFL | EA | D | | | | | | | | | |
| drfp385 | MRSSKNV | KEFR | R | K | R | E | STNGH | E | E | E | R | PYEH | T | K | K | TKGGFL | EA | D | | | | |
| gfp | MSKGEEL | TGV | P | EL | E | D | ONCH | S | S | E | E | E | D | ATY | K | T | K | I | TT | GKL | EA | D |
| Consensus | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|-----------|----|---|----|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| poc4 | QY | G | P | E | K | P | E | D | I | - | P | K | P | E | G | T | W | E | I | N | E | D | G | A | V | T | S | D | S | I | Q | G | N | C | | | | |
| drfp385 | QY | G | P | E | K | P | A | D | I | - | P | K | P | E | G | T | W | E | I | N | E | D | G | A | V | T | T | D | S | I | Q | D | G | C | | | | |
| gfp | SV | P | SV | G | P | E | K | P | D | H | M | K | R | H | E | K | S | P | E | G | V | Q | E | T | F | K | D | D | G | N | K | R | E | K | E | G | D | T |
| Consensus | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : |

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|-----------|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| poc4 | I | H | M | K | S | G | L | N | P | P | N | G | P | - | Q | K | T | G | W | E | P | T | R | F | A | - | R | D | G | M | I | N | S | F | A | K | L | E | G | G | - | H | Y | | | | | |
| drfp385 | I | K | K | I | G | V | N | P | S | D | G | P | - | Q | K | T | G | W | E | A | S | T | R | L | Y | P | - | R | D | G | V | K | G | E | H | A | K | L | K | D | G | - | H | Y | | | | |
| gfp | V | E | R | E | K | I | D | K | E | D | G | N | S | G | H | K | E | E | N | Y | N | S | N | I | N | I | - | M | A | D | K | Q | K | N | G | K | N | K | R | I | N | I | E | D | G | S | V | L |
| Consensus | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | |

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|-----------|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|--|
| poc4 | C | S | F | S | T | Y | K | A | K | - | P | V | R | M | P | G | Y | T | D | K | D | T | N | H | N | K | O | Y | T | S | - | V | E | C | I | S | I | R | K | P | V | V | A | W | C | F | F | R | V | > | | | |
| drfp385 | V | E | C | S | T | Y | M | A | K | - | F | V | Q | L | P | G | Y | T | D | K | D | T | S | H | N | E | D | Y | T | I | - | V | E | C | I | S | I | R | K | P | V | V | A | W | C | F | F | R | V | > | | | |
| gfp | D | I | V | E | C | T | P | I | G | D | G | P | V | L | L | P | D | N | I | Y | S | I | O | A | S | K | O | P | N | E | K | R | D | H | V | E | L | F | T | A | G | I | T | | | | | | | | | | |
| Consensus | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | : | |

(SEQ ID NO: 4)

(SEQ ID NO: 9)

(SEQ ID NO: 10)

(SEQ ID NO: 4)

(SEQ ID NO: 8)

(SEQ ID NO: 10)

WO 00/46233

PCT/AU00/00056

20

Table 3. Maximal absorbance, and excitation and corresponding emission peaks of GFP-like proteins in reef-building corals.

| Coral Species | Colour | Absorbance (nm) | Excitation (nm) | Emission (nm) |
|---------------------------------|-------------|--------------------|------------------------------|-----------------------------|
| <i>Pocillopora damicornis</i> | Pink | 560 | 358 484 570 | 440* 499* 625 |
| <i>Seriatopora hystrix</i> | Pink | 560 | 462 | 482 |
| <i>Acropora digitifera</i> + | Purple-blue | 578 (550 shoulder) | 425 570 | 490 590 |
| <i>Acropora horrida</i> + | Blue | 579 | 345 420 575 | 400 485 625 |
| <i>Acropora aspera</i> | Blue | 580 (550 shoulder) | 340 420-450 480 576 | 445* 490* 500 630* |
| <i>Montipora monasteriata</i> + | Purple | 574-578 | 420-450 570 | 490 610 |
| <i>Montipora caliculata</i> + | Purple | 579 (545 shoulder) | 420-450-465 | 485 |
| <i>Porites lobata</i> | | 576 (545 shoulder) | | |
| <i>Porites murrayensis</i> + | Purple | 576 (545 shoulder) | 420 530 570 | 485 550 625 |
| <i>Plesiastrea versipora</i> | Green | 492 | 492 | 505 |

* indicate pigments profiles that are shown in Figure 9.

+ means same gel filtration fraction as that used in preparation for sequencing.

WO 00/46233

PCT/AU00/00056

21

Table 4. Residues within 5 Å of the fluorophore, with details of atomic contacts. Atom numbers are in accordance with PDB nomenclature.

Interactions stabilizing the resonance forms of the fluorophore are in bold.

| <u>Protein</u> | | <u>Fluorophore</u> | | <u>Distance</u> |
|----------------|------|--------------------|------|-----------------|
| Residue | Atom | Residue | Atom | (Å) |
| Glu-210 | OE2 | Gln-61 | OE1 | 2.5 |
| Ser-64 | N | Gly-63 | O | 2.6 |
| Arg-90 | NH2 | Tyr-62 | O | 2.7 |
| Arg-192 | NH1 | Tyr-62 | OH | 2.7 |
| Glu-210 | OE1 | Gln-61 | NE2 | 2.7 |
| Ser-57 | O | Gln-61 | N | 2.9 |
| Gln-37 | OE1 | Gln-61 | CG | 3.0 |
| Pro-58 | O | Gly-63 | N | 3.0 |
| Val-39 | CG1 | Gln-61 | OE1 | 3.3 |
| Glu-143 | OE1 | Tyr-62 | CD2 | 3.4 |
| Tyr-115 | CD2 | Gly-63 | O | 3.5 |
| Ser-106 | OG | Gly-63 | O | 3.6 |
| Asn-141 | CB | Tyr-62 | OH | 3.7 |
| Leu-194 | CD2 | Tyr-62 | CE1 | 3.7 |
| Tyr-86 | OH | Gly-63 | O | 4.2 |
| Met-158 | CE | Tyr-62 | OH | 4.2 |
| Gln-208 | CB | Gln-61 | NE2 | 4.3 |
| Glu-139 | O | Tyr-62 | OH | 4.5 |
| Asn-156 | OD1 | Tyr-62 | CE2 | 4.6 |
| Glu-171 | O | Tyr-62 | CD2 | 4.7 |
| Leu-56 | O | Gln-61 | N | 4.8 |
| Trp-88 | NE1 | Tyr-62 | O | 4.8 |
| Cys-209 | O | Gln-61 | NE2 | 5.0 |

WO 00/46233

PCT/AU00/00056

22

Example 3:

POC3 and POC4 were PCR amplified out of the pGEM-EASY cloning vector using the following forward and reverse primers:

5 POC (FORWARD): 5'-TCC GTT ATC GCT AAA CAG AT-3'
(SEQ ID NO: 11)
POC3(231) (REVERSE): 5'-TTT GTG CCT TGA TTT GAC TC-3'
(SEQ ID NO: 12)
POC4(235) (REVERSE): 5'-CGC CAC TGC GTA TTT GTG CC-3'
10 (SEQ ID NO: 13)
POC4(220) (REVERSE): 5'-GGC GACCAC AGG TTT GCG TG-3'
(SEQ ID NO: 14)

15 Amplified sequences were gel purified and inserted into the bacterial pBAD TOPO expression vector using the pBAD TOPO TA cloning kit (Invitrogen, Carlsbad, CA, USA), prior to transformation into One Shot Competent Cells (Invitrogen, Carlsbad, CA, USA). Reading frame and occurrence of stop codon at position AA221 in longer sequences (231 amino acids and 235 amino acids) were checked by ABI nucleotide sequencing from
20 pBAD forward and reverse priming sites in the pBAD TOPO expression vector.

Protein expression from pBAD TOPO was regulated by optimising Arabinose concentration. Expressed proteins are purified by: (i) binding the 6 x His tag that is synthesised at the C-terminus of proteins engineered to use
25 the pBAD TOPO transcription stop codon, and (ii) by gel filtration chromatography for expressed proteins lacking the 6 x His tag.

Example 4:

30 The ability of PPCTs to absorb light in the range of 320 - 700 nm, which covers UVA and UVB radiation makes them useful screening components of sunscreen formulations. Such formulations would include, for example, an effective screening amount of PPCT, optionally in admixture with a pharmaceutically acceptable carrier or excipient. Sunscreen formulations including PPCT may be produced by forming an emulsion by
35 mixing PPCT with an agent or composition which renders the PPCT non-water soluble. Alternatively, the PPCT may be synthesised with a "tag"

WO 00/46233

PCT/AU00/00056

23

peptide or compound such as a long chain fatty acid (e.g. by linking the "tag" to, or near, the C-terminus of the PPCT), to render the PPCT non-water soluble and thereby capable of forming an emulsion in an aqueous carrier or excipient. Methods of acylating proteins at, for example, carboxy or amino groups (e.g. ϵ -amino groups) of proteins are well known in the art. The amount of PPCT present in a sunscreen formulation would generally be at least 1% by weight of the formulation. A preferred sunscreen formulation including PPCT (acylated with a fatty acid with greater than 10 carbon atoms) comprises:

- (i) about 3% cetostearyl alcohol, PEG-40 castor oil and/or sodium cetearyl sulphate,
- (ii) about 10% decyl oleate,
- (iii) about 1.5% sodium hydroxide (45% solution),
- (iv) about 0.1 to 0.5% disodium edetate,
- (v) about 0.5% carbomer,
- (vi) about 1 to 10% acylated PPCT, and
- (vii) the balance being water.

The sunscreen formulation may also include other screening agents well known in the art, for example, propyl hydroxybenzoate, dimethylaminobenzoate (PABA), phenyl salicylates, and/or octyl methoxycinnamate.

Example 5:

The ability of PPCTs to absorb light in the range of 320 - 700 nm also makes them useful for incorporation into various materials such as glass and polymeric materials such as perspex for use as filters for application in, for example, sunglass lenses, cameras, aquariums and greenhouses.

The absorbance range of PPCTs of 320 - 700 nm covers the solet band (430 nm) of chlorophyll *a*, but more specifically the Q_x band of chlorophyll *a* and *c* (550-600nm). The Q_x band specifically absorbs scattered light associated with high light intensities. PPCTs incorporated into filters may therefore function to reduce photoinhibition of plants in high light environments. Further the ability of PPCTs to emit light at a wavelength higher than their excitation or maximal absorbance wavelength provides the possibility of transmitting across, for example, glass, the energy associated with light wavelengths which would not otherwise be transmitted. Where

WO 00/46233

PCT/AU00/00056

24

that energy is transferred at a wavelength in the range of photosynthetically active radiation (PAR), that is 400 - 550 nm, the use of PPCT in filters offers the possibility of generating improved growing conditions for plants, algae, corals etc. For example, use of the PPCT from *A. horrida* which is excited by light of 320 - 360 nm, would allow the absorbance of UVA light (which is not greatly transmitted by glass) to be retransmitted at the PAR wavelength of 430 - 450 nm.

The high-temperature tolerance of PPCT ($>40^{\circ}\text{C}$) enables PPCT to be readily included into, or coated onto, glass and other polymeric materials (especially polymeric materials with relatively low melting temperatures). The amount of PPCT included in glass and other polymeric materials, or alternatively included into a coating material, would generally be greater than 1 % by weight.

WO 00/46233

PCT/AU00/00056

25

It will be appreciated by persons skilled in the art that numerous variations and/or modifications may be made to the invention as shown in the specific embodiments without departing from the spirit or scope of the invention as broadly described. The present embodiments are, therefore, to be considered in all respects as illustrative and not restrictive.

5

WO 00/46233

PCT/AU00/00056

26

Claims:-

1. An isolated polynucleotide molecule comprising a nucleotide sequence encoding a pigment protein from coral tissue (PPCT) capable of emitting fluorescence upon irradiation by incident light, wherein maximal absorbance of said incident light is in the range of 320 - 600 nm, and maximal fluorescence emission is in the range 300 - 700 nm.
2. The isolated polynucleotide molecule of claim 1, wherein the encoded pigment protein has a maximal absorbance of said incident light in the range of 550 - 580 nm, and a maximal fluorescence emission in the range 400 - 630 nm).
3. An isolated polynucleotide molecule comprising a nucleotide sequence encoding a pigment protein from coral tissue (PPCT), wherein said molecule comprises a nucleotide sequence encoding a protein having the N-terminal amino acid sequence:
SVIAK (SEQ ID NO: 1).
4. An isolated polynucleotide molecule comprising a nucleotide sequence encoding a pigment protein from coral tissue (PPCT), wherein said molecule comprises a nucleotide sequence encoding a protein having the N-terminal amino acid sequence:
SVIAKQMTYKVYMSGTV (SEQ ID NO: 2).
5. The isolated polynucleotide molecule of any one of the preceding claims, wherein the encoded protein includes a chromatophore region comprising the amino acid sequence: QYG.
6. The isolated polynucleotide molecule of any one of the preceding claims, wherein said molecule comprises a nucleotide sequence encoding a protein having an amino acid sequence corresponding to the sequence shown as SEQ ID NO: 3 or 4.

WO 00/46233

PCT/AU00/00056

. 27

7. The isolated polynucleotide molecule of any one of the preceding claims, wherein said molecule comprises a nucleotide sequence which has at least 80% identity to the sequence shown as SEQ ID NO: 5 or 6.
- 5 8. The isolated polynucleotide molecule of claim 7, wherein said molecule comprises a nucleotide sequence which has at least 90% identity to the sequence shown as SEQ ID NO: 5 or 6.
- 10 9. The isolated polynucleotide molecule of claim 7, wherein said molecule comprises a nucleotide sequence which has at least 95% identity to the sequence shown as SEQ ID NO: 5 or 6.
- 15 10. The isolated polynucleotide molecule of any one of the preceding claims, wherein said molecule comprises a nucleotide sequence substantially corresponding to the sequence shown as SEQ ID NO: 5 or 6.
- 20 11. A protein comprising the N-terminal amino acid sequence:
SVIAK (SEQ ID NO: 1), said protein being in a substantially purified form.
- 25 12. A protein comprising the N-terminal amino acid sequence:
SVIAKQMTYKVYMSGTVN (SEQ ID NO: 2), said protein being in a substantially purified form.
- 30 13. The protein of claim 11 or 12, wherein said protein comprises an amino acid sequence corresponding to the sequence shown as SEQ ID NO: 3 or 4.
- 35 14. The protein of any one of claims 11 to 13, wherein said protein can be purified from coral tissue from a coral family selected from the group consisting of: Pocilloporidae, Acroporidae, Poritidae, Faviidae, Merulinidae and Fungiidae.
15. The protein of claim 14, wherein said protein can be purified from tissue of coral selected from the group consisting of: *Acropora aspera*.

WO 00/46233

PCT/AU00/00056

28

Acropora digitifera, *Acropora horrida*, *Acropora formosa*, *Montipora monasteriata*, *Montipora caliculata*, *Pocillopora damicornis*, *Porites murrayensis*, *Porites lobata*, *Plesiastrea versipora* and *Seriatopora hystrix*.

- 5
16. The protein of claim 14, wherein said protein can be purified from tissue of coral selected from the group consisting of: *Acropora aspera*, *Acropora horrida*, *Montipora monasteriata*, *Montipora caliculata*, *Porites murrayensis*, *Porites lobata*, and *Plesiastrea versipora*.
- 10
17. A vector comprising a polynucleotide molecule according to any one of claims 1 to 10.
18. A host cell transfected or transformed with the vector of claim 17.
- 15
19. A process for producing the protein of any one of claims 11 to 16, wherein the process comprises the step of cultivating a host cell transfected or transformed with a vector according to claim 17 under conditions suitable for expression of the polynucleotide molecule encoding the protein, and optionally recovering the expressed protein.
- 20
20. The process of claim 19, wherein the step of cultivating a host cell is conducted at a temperature in the range of 30 - 37°C.
- 25
21. The process of claim 19, wherein the step of cultivating a host cell is conducted at a temperature of about 35°C.
22. An oligonucleotide probe or primer comprising a nucleotide sequence that hybridises selectively to a polynucleotide molecule according to any one of claims 1 to 10.
- 30
23. The oligonucleotide probe or primer of claim 22, wherein said probe or primer comprises at least 8 nucleotides.
- 35
24. The oligonucleotide probe or primer of claim 22, wherein said probe or primer comprises at least 18 nucleotides.

WO 00/46233

PCT/AU00/00056

29

25. The oligonucleotide probe or primer of claim 22, wherein said probe or primer comprises at least 25 nucleotides.

5 26. The oligonucleotide probe or primer of any one of claims 22 to 25, wherein the oligonucleotide is conjugated to a detectable label.

27. Use of a protein according to any one of claims 11 to 16 as a tissue marker, fluorescent marker or general dyestuff.

10

28. A sunscreen formulation comprising an effective amount of a protein according to any one of claims 11 to 16, in admixture with a suitable pharmaceutical acceptable carrier or excipient.

15

29. A filter for screening UV or other wavelength(s) of incident light comprising an effective amount of a protein according to any one of claims 11 to 16.

20

30. The filter of claim 29, wherein the UV or other wavelength(s) of incident light is screened by absorption of the energy associated with said light by said protein and is then emitted at a longer wavelength than said incident light.

25

31. The filter of claim 30, wherein the absorbed energy of said incident light is emitted from said protein at a wavelength in the range of 400 to 550 nm.

WO 00/46233

PCT/AU00/00056

1/10

DEGENERATIVE OLIGOMER (30-MER):

TCCGTTATCGCTAAACAGATGACCTACAAA

(SEQ ID NO: 15)

Figure 1

Figure 1 is a schematic diagram of the degenerative oligomer (30-MER) sequence. The sequence is represented by a series of vertical bars of varying heights, indicating the relative frequency or probability of each nucleotide at each position. The sequence is TCCGTTATCGCTAAACAGATGACCTACAAA. The bars are arranged in a way that suggests a high degree of conservation for the first 10 positions (TCCGTTATCG) and a more variable region for the last 10 positions (GACCTACAAA). The middle 10 positions (CTAAACAGAT) show a mix of conservation and variability.

Ove HOECH-GULDBERG et al
"PIGMENT PROTEIN..."
Q-65619

09/890463

PCT/AU00/00056

Figure 2

[illegible]

09/890463

WO 00/46233

PCT/AU00/00056

3/10

BASPOC3.pap

1 SVIAKQMTYK VYMSGTVNGH YFEVEGDGKG KPYEGEQTVR LAVTKGGPLP
51 FAWDILSPQC QYGSIPFTKY PEDIPDYVKQ SFPGRYTWER IMNFEDGAVC
101 TVSNDSSIQG NCFIYHVKFS GLNFPPNGPV MQKKTQGWEP NTERLFARDG
151 MLIGNNFMAL KLEGGGHYLC EFKSTYKARK PVKMPGYHYV DRKLDVTNHN
201 KDYTSVEQRE ISIARKPLVA CCFFRVKSRH K* (SEQ IN NO: 3)

In bold, differences between clones.

Figure 3

09/890463

WO 00/46233

PCT/AU00/00056

4/10

BASPOC4.pep

1 SVIAKQMTYK VYMSGTVNGH YFEVEGDGKG KPYEGEQTVR LAVTKGGPLP
51 FAWDILSPQC QYGSIPFTKY PEDIPDYVKQ SFPGRYTWER IMNFEDGAVC
101 TVSNDSSIQG NCFIYHVKFS GLNFFPNGPV MQKKTQGWEP NTERLFARDG
151 MLIGNNFMAL KLEGGGHYLC EFKSTYKAKK PVKMPGYHYV DRKLDVTNHN
201 KDYTSVEQCE ISIARKPVVA CRFFRVKSRH KYAVA* (SEQ ID NO: 4)

Figure 4

09/890463

WO 00/46233

PCT/AU00/00056

5/10

t7SP6BASPOC3 Length: 841

| | | | | | |
|-----|------------|------------|------------|------------|------------------|
| 1 | TCCGTTATCG | CTAAACAGAT | GACCTACAAA | GTTTATATGT | CAGGCACGGT |
| 51 | CAATGGACAC | TACTTTGAGG | TCGAAGGCGA | TGGAAAAGGA | AAGCCTTACG |
| 101 | AGGGGGAGCA | GACGGTAAGG | CTGGCTGTCA | CCAAGGGCGG | ACCTCTGCCA |
| 151 | TTTGCTTGGG | ATATTTTATC | ACCACAGTGT | CAGTACGGAA | GCATACCATT |
| 201 | CACCAAGTAC | CCTGAAGACA | TCCCTGACTA | TGTAAAGCAG | TCATTCCCGG |
| 251 | GGAGATATAC | ATGGGAGAGG | ATCATGAACT | TTGAAGATGG | TGCAGTGTGT |
| 301 | ACTGTCAGCA | ATGATTCCAG | CATCCAAGGC | AACTGTTTCA | TCTACCATGT |
| 351 | CAAGTTCTCT | GGTTTGAACT | TTCTTCCCAA | TGGACCTGTT | ATGCAGAAGA |
| 401 | AGACACAGGG | CTGGGAACCC | AACACTGAGC | GTCTCTTTGC | ACGAGATGGA |
| 451 | ATGCTGATAG | GAAACAACCT | TATGGCTCTG | AAGTTAGAAG | GAGGTGGTCA |
| 501 | CTATTTGTGT | GAATTCAAAT | CTACTTACAA | GGCAAGGAAG | CCTGTGAAGA |
| 551 | TGCCAGGGTA | TCACTATGTT | GACCGCAAAC | TGGATGTAAC | CAATCACAAAC |
| 601 | AAGGATTACA | CTTCCGTTGA | GCAGCGTGAA | ATTTCCATTG | CACGCAAACC |
| 651 | TTTGGTCGCC | TGCTGTTTTT | TCAGAGTCAA | ATCAAGGCAC | AAATAAGCAG |
| 701 | TGGCGTAAAA | AACGTAGATT | CTGATTTTAG | CTTAGAGAAG | TAGGAACGAA |
| 751 | GAAGTGTAGA | CAACCTTCAA | TGATTAAACT | TTTGAAAACA | ACSCCAAAAA |
| 801 | AAAAAAAAAA | AAAAAAAAAA | AAAAAGCGGC | CGCTCGAATT | A (SEQ ID NO: 5) |

663 either A or C
In bold differences

Figure 5

09/890463

WO 00/46233

PCT/AU00/00056

6/10

T7SP6BASPOC4 Length: 841 (today) Check: 7145 ..

| | | | | | |
|-----|------------|------------|-------------|------------|------------------|
| 1 | TCCGTTATCG | CTAAACAGAT | GACCTACAAA | GTTTATATGT | CAGGCACGGT |
| 51 | CAATGGACAC | TACTTTGAGG | TCGAAGGCCA | TGGAAAAGGA | AAGCCTTACG |
| 101 | AGGGGGAGCA | GACGGTAAGG | CTGGCTGTCA | CCAAGGGCGG | ACCTCTGCCA |
| 151 | TTTGCTTGGG | ATATTTTATC | ACCACAGTGT | CAGTACGGAA | GCATACCATT |
| 201 | CACCAAGTAC | CCTGAAGACA | TCCCTGACTA | TGTAAAGCAG | TCATTCCCGG |
| 251 | GGAGATATAC | ATGGGAGAGG | ATCATGAACT | TTGAAGATGG | TGCAGTGTGT |
| 301 | ACTGTCAGCA | ATGATTCCAG | CATCCAAGGC | AACTGTTTCA | TCTACCATGT |
| 351 | CAAGTTCTCT | GGTTTGAACT | TTCCTCCCAA | TGGACCTGTT | ATGCAGAAGA |
| 401 | AGACACAGGG | CTGGGAACCC | AACACTGAGC | GTCTCTTTGC | ACGAGATGGA |
| 451 | ATGCTGATAG | GAAACAACCT | TATGGCTCTG | AAGTTAGAAG | GAGGTGGTCA |
| 501 | CTATTTGTGT | GAATTCAAAT | CTACTTACAA | GGCAAAGAAG | CCTGTGAAGA |
| 551 | TGCCAGGGTA | TCACTATGTT | GACCGCAAAAC | TGGATGTAAC | CAATCACAAAC |
| 601 | AAGGATTACA | CTTCCGTTGA | GCAGTGTGAA | ATTTCCATTG | CACGCAAACC |
| 651 | TGTGGTCGCC | TGCCGTTTTT | TCAGAGTCAA | ATCAAGGCAC | AAATACGCAG |
| 701 | TGGCGTAAAA | AACGTAGATT | CTGATTTTAG | CTTATAGAAG | TAGGAACGAA |
| 751 | GAAGTGTAAG | CAACCATTAA | TGATTAAACT | TTTGAAAACA | ACGCCATAAA |
| 801 | AAAAAAAAAA | AAAAAAAAAA | AAAAAGCGGC | CGCTCGAATT | A (SEQ ID NO: 6) |

Figure 6

09/890463

WO 00/46233

PCT/AU00/00056

7/10

COLORED PROTEIN VECTOR




Figure 7.

WO 00/46233

PCT/AU00/00056

8/10




Figure 8

WO 00/46233

PCT/AU00/00056

9/10




Figure 9

WO 00/46233

PCT/AU00/00056

10/10




Figure 10

DECLARATION AND POWER OF ATTORNEY

As the below named inventors, we hereby declare that our residence, post office address and citizenships are as stated below next to our names: that we verily believe we are the original and joint inventors of the subject matter claimed and for which a patent is sought in the application entitled:

PIGMENT PROTEIN FROM CORAL TISSUE

which application is:

☐ the attached application
(for original application)

PCT/AU00/00056 filed February 2, 2000
☒ Application No. 09/890,463
filed August 1, 2001, and amended on
August 1, 2001
(for declaration not accompanying application)

that we have reviewed and understand the contents of the specification of the above-identified application, including the claims, as amended by any amendment referred to above; that we acknowledge our duty to disclose information of which we are aware which is material to the patentability of this application under 37 C.F.R. § 1.56, that we hereby claim priority benefits under Title 35, United States Code §119, §172 or §365 of any provisional application or foreign application(s) for patent or inventor's certificate listed below and have also identified on said list any foreign application for patent or inventor's certificate on this invention having a filing date before that of any foreign application on which priority is claimed:

| Application Number | Country | Filing Date | Priority Claimed |
|--------------------|-----------|------------------|------------------|
| AU 00/00056 | PCT | February 2, 2000 | YES |
| PP8463 | AUSTRALIA | February 2, 1999 | YES |

We hereby claim the benefit of Title 35, United States Code §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in a listed prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, We acknowledge our duty to disclose any information material to the patentability of this application under 37 C.F.R. 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

| Application No. | Filing Date | Status |
|-----------------|-------------|--------|
|-----------------|-------------|--------|

(30) We hereby appoint John H. Mion, Reg. No. 18,879; Thomas J. Macpeak, Reg. No. 19,292; Robert J. Seas, Jr., Reg. No. 21,092; Darryl Mexic, Reg. No. 23,063; Robert V. Sloan, Reg. No. 22,775; Peter D. Olexy, Reg. No. 24,513; J. Frank Osha, Reg. No. 24,625; Waddell A. Biggart, Reg. No. 24,861; Louis Gubinsky, Reg. No. 24,835; Neil B. Siegel, Reg. No. 25,200; David J. Cushing, Reg. No. 28,703; John R. Inge, Reg. No. 26,916; Joseph J. Ruch, Jr., Reg. No. 26,577; Sheldon I. Landsman, Reg. No. 25,430; Richard C. Turner, Reg. No. 29,710; Howard L. Bernstein, Reg. No. 25,665; Alan J. Kasper, Reg. No. 25,426; Kenneth J. Burchfiel, Reg. No. 31,333; Gordon Kit, Reg. No. 30,764; Susan J. Mack, Reg. No. 30,951; Frank L. Bernstein, Reg. No. 31,484; Mark Boland, Reg. No. 32,197; William H. Mandir, Reg. No. 32,156; Scott M. Daniels, Reg. No. 32,562; Brian W. Hannon, Reg. No. 32,778; Abraham J. Rosner, Reg. No. 33,276; Bruce E. Kramer, Reg. No. 33,725; Paul F. Neils, Reg. No. 33,102; Brett S. Sylvester, Reg. No. 32,765; Robert M. Masters, Reg. No. 35,603 and George F. Lehnigk, Reg. No. 36,359, our attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and request that all correspondence about the application be addressed to **SUGHRUE, MION, ZINN, MACPEAK & SEAS, PLLC**, 2100 Pennsylvania Avenue, N.W., Washington, D.C. 20037-3213.

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Date 18th September 2001 First Inventor Ove HOECH-GULDBERG
Residence Queensland AUSTRALIA Signature Ove Hoegh-Guldberg
City AUSTRALIA State/Country
Post Office Address: c/o Centre for Marine Studies, University of Queensland
Brisbane, Queensland 4072, AUSTRALIA
Citizenship AUSTRALIAN

200 Date 18/9/01 Second Inventor Sophie DOVE
First Name Middle Initial Last Name
Residence Queensland AUSTRALIA AUX Signature [Signature]
City State/Country

Post Office Address: c/o Centre for Marine Studies, University of Queensland
Brisbane, Queensland 4072, AUSTRALIA

Citizenship AUSTRALIAN

Date _____ Third Inventor _____
First Name Middle Initial Last Name

Residence _____ Signature _____
City State/Country

Post Office Address: _____

Citizenship _____

Date _____ Fourth Inventor _____
First Name Middle Initial Last Name

Residence _____ Signature _____
City State/Country

Post Office Address: _____

Citizenship _____

Date _____ Fifth Inventor _____
First Name Middle Initial Last Name

Residence _____ Signature _____
City State/Country

Post Office Address: _____

Citizenship _____

Date _____ Sixth Inventor _____
First Name Middle Initial Last Name

Residence _____ Signature _____
City State/Country

Post Office Address: _____

Citizenship _____

09/890463

WO 00/46233

PCT/AU00/00056

1

Sequence Listing:

<110> The University of Sydney

<120> Pigment protein from coral tissue

<160> 15

<170> PatentIn Ver. 2.1

<210> 1

<211> 5

<212> PRT

<213> Acropora aspera, Acropora horrida, Montipora caliculata, Porites murrayensis, Montipora monasteriata, and Porites lobata

<400> 1

Ser Val Ile Ala Lys

1

5

<210> 2

<211> 17

<212> PRT

<213> Acropora horrida

<400> 2

Ser Val Ile Ala Lys Gln Met Thr Tyr Lys Val Tyr Met Ser Gly Thr

1

5

10

15

Val

<210> 3

<211> 231

<212> PRT

<213> Acropora aspera

<400> 3

Ser Val Ile Ala Lys Gln Met Thr Tyr Lys Val Tyr Met Ser Gly Thr

1

5

10

15

Val Asn Gly His Tyr Phe Glu Val Glu Gly Asp Gly Lys Gly Lys Pro

20

25

30

Tyr Glu Gly Glu Gln Thr Val Arg Leu Ala Val Thr Lys Gly Gly Pro

35

40

45

Leu Pro Phe Ala Trp Asp Ile Leu Ser Pro Gln Cys Gln Tyr Gly Ser

50

55

60

Ile Pro Phe Thr Lys Tyr Pro Glu Asp Ile Pro Asp Tyr Val Lys Gln

65

70

75

80

Ser Phe Pro Gly Arg Tyr Thr Trp Glu Arg Ile Met Asn Phe Glu Asp

85

90

95

Gly Ala Val Cys Thr Val Ser Asn Asp Ser Ser Ile Gln Gly Asn Cys

100

105

110

WO 00/46233

PCT/AU00/00056

2

Phe Ile Tyr His Val Lys Phe Ser Gly Leu Asn Phe Pro Pro Asn Gly
 115 120 125
 Pro Val Met Gln Lys Lys Thr Gln Gly Trp Glu Pro Asn Thr Glu Arg
 130 135 140
 Leu Phe Ala Arg Asp Gly Met Leu Ile Gly Asn Asn Phe Met Ala Leu
 145 150 155 160
 Lys Leu Glu Gly Gly Gly His Tyr Leu Cys Glu Phe Lys Ser Thr Tyr
 165 170 175
 Lys Ala Arg Lys Pro Val Lys Met Pro Gly Tyr His Tyr Val Asp Arg
 180 185 190
 Lys Leu Asp Val Thr Asn His Asn Lys Asp Tyr Thr Ser Val Glu Gln
 195 200 205
 Arg Glu Ile Ser Ile Ala Arg Lys Pro Leu Val Ala Cys Cys Phe Phe
 210 215 220
 Arg Val Lys Ser Arg His Lys
 225 230

<210> 4
 <211> 235
 <212> PRT
 <213> *Acropora aspera*

<400> 4
 Ser Val Ile Ala Lys Gln Met Thr Tyr Lys Val Tyr Met Ser Gly Thr
 1 5 10 15
 Val Asn Gly His Tyr Phe Glu Val Glu Gly Asp Gly Lys Gly Lys Pro
 20 25 30
 Tyr Glu Gly Glu Gln Thr Val Arg Leu Ala Val Thr Lys Gly Gly Pro
 35 40 45
 Leu Pro Phe Ala Trp Asp Ile Leu Ser Pro Gln Cys Gln Tyr Gly Ser
 50 55 60
 Ile Pro Phe Thr Lys Tyr Pro Glu Asp Ile Pro Asp Tyr Val Lys Gln
 65 70 75 80
 Ser Phe Pro Gly Arg Tyr Thr Trp Glu Arg Ile Met Asn Phe Glu Asp
 85 90 95
 Gly Ala Val Cys Thr Val Ser Asn Asp Ser Ser Ile Gln Gly Asn Cys
 100 105 110
 Phe Ile Tyr His Val Lys Phe Ser Gly Leu Asn Phe Pro Pro Asn Gly
 115 120 125
 Pro Val Met Gln Lys Lys Thr Gln Gly Trp Glu Pro Asn Thr Glu Arg
 130 135 140
 Leu Phe Ala Arg Asp Gly Met Leu Ile Gly Asn Asn Phe Met Ala Leu
 145 150 155 160

WO 00/46233

PCT/AU00/00056

3

Lys Leu Glu Gly Gly Gly His Tyr Leu Cys Glu Phe Lys Ser Thr Tyr
 165 170 175

Lys Ala Lys Lys Pro Val Lys Met Pro Gly Tyr His Tyr Val Asp Arg
 180 185 190

Lys Leu Asp Val Thr Asn His Asn Lys Asp Tyr Thr Ser Val Glu Gln
 195 200 205

Cys Glu Ile Ser Ile Ala Arg Lys Pro Val Val Ala Cys Arg Phe Phe
 210 215 220

Arg Val Lys Ser Arg His Lys Tyr Ala Val Ala
 225 230 235

<210> 5
 <211> 841
 <212> DNA
 <213> *Acropora aspera*

<400> 5
 tccgttatcg ctaaacagat gacctacaaa gtttatatgt caggcacggt caatggacac 60
 tactttgagg tcgaaggcga tggaaaagga aagccttacg agggggagca gacggtaagg 120
 ctggctgtca ccaagggcgg acctctgcc aattgttggg atattttatc accacagtgt 180
 cagtacggaa gcataccatt caccaagtac cctgaagaca tccctgacta tgtaaagcag 240
 tcattccogg ggagatatac atgggagagg atcatgaact ttgaagatgg tgcagtgtgt 300
 actgtcagca atgattccag catccaaggg aactgtttca tctaccatgt caagttctct 360
 ggtttgaact ttctctccaa tggacctgtt atgcagaaga agacacaggg ctgggaacce 420
 aacactgagc gtctctttgc acgagatgga atgctgatag gaaacaactt tatggctctg 480
 aagttagaag gaggtggtca ctatttgtgt gaattcaaat ctacttacaa ggcaaggaa 540
 cctgtgaaga tgcacagggt tcaactatgtt gaccgcaaac tggatgtaac caatcacaac 600
 aaggattaca cttccgttga gcagcgtgaa atttccattg cagcgaaccc ttgggtcgcc 660
 tgctgttttt tcagagtcaa atcaaggcac aaataagcag tggcgtaaaa aacgtagatt 720
 ctgatttttag cttatagaag taggaacgaa gaagtgtaga caaccctcaa tgattaaact 780
 tttgaaaaca acsccaaaaa aaaaaaaaaa aaaaaaaaaa aaaaagcggc cgctcgaatt 840
 a 841

<210> 6
 <211> 841
 <212> DNA
 <213> *Acropora aspera*

<400> 6
 tccgttatcg ctaaacagat gacctacaaa gtttatatgt caggcacggt caatggacac 60
 tactttgagg tcgaaggcga tggaaaagga aagccttacg agggggagca gacggtaagg 120
 ctggctgtca ccaagggcgg acctctgcc aattgttggg atattttatc accacagtgt 180
 cagtacggaa gcataccatt caccaagtac cctgaagaca tccctgacta tgtaaagcag 240
 tcattccogg ggagatatac atgggagagg atcatgaact ttgaagatgg tgcagtgtgt 300
 actgtcagca atgattccag catccaaggg aactgtttca tctaccatgt caagttctct 360
 ggtttgaact ttctctccaa tggacctgtt atgcagaaga agacacaggg ctgggaacce 420
 aacactgagc gtctctttgc acgagatgga atgctgatag gaaacaactt tatggctctg 480
 aagttagaag gaggtggtca ctatttgtgt gaattcaaat ctacttacaa ggcaaggaa 540
 cctgtgaaga tgcacagggt tcaactatgtt gaccgcaaac tggatgtaac caatcacaac 600
 aaggattaca cttccgttga gcagcgtgaa atttccattg cagcgaaccc ttgggtcgcc 660
 tgccgttttt tcagagtcaa atcaaggcac aaataagcag tggcgtaaaa aacgtagatt 720
 ctgatttttag cttatagaag taggaacgaa gaagtgtaaa caaccattaa tgattaaact 780
 tttgaaaaca acgccataaa aaaaaaaaaa aaaaaaaaaa aaaaagcggc cgctcgaatt 840
 a 841

WO 00/46233

PCT/AU00/00056

4

<210> 7
 <211> 18
 <212> PRT
 <213> *Acropora aspera*, *Montipora caliculata*, and *Porites murrayensis*

<400> 7
 Ser Val Ile Ala Lys Gln Met Thr Tyr Lys Val Tyr Met Ser Gly Thr
 1 5 10 15

Val Asn

<210> 8
 <211> 25
 <212> PRT
 <213> *Porites lobata*

<400> 8
 Ser Val Ile Ala Lys Gln Met Thr Tyr Lys Val Tyr Met Ser Gly Thr
 1 5 10 15

Val Asn Asn His Tyr Glu Phe Val Thr
 20 25

<210> 9
 <211> 225
 <212> PRT
 <213> *Discosoma* sp.

<400> 9
 Met Arg Ser Ser Lys Asn Val Ile Lys Glu Phe Met Arg Phe Lys Val
 1 5 10 15
 Arg Met Glu Gly Thr Val Asn Gly His Glu Phe Glu Ile Glu Gly Glu
 20 25 30
 Gly Glu Gly Arg Pro Tyr Glu Gly His Asn Thr Val Lys Leu Lys Val
 35 40 45
 Thr Lys Gly Gly Pro Leu Pro Phe Ala Trp Asp Ile Leu Ser Pro Gln
 50 55 60
 Phe Gln Tyr Gly Asn Lys Val Tyr Val Lys His Pro Ala Asp Ile Pro
 65 70 75 80
 Asp Tyr Lys Lys Leu Ser Phe Pro Glu Gly Phe Lys Trp Glu Arg Trp
 85 90 95
 Met Asn Phe Glu Asp Gly Gly Val Val Thr Val Thr Gln Asp Ser Ser
 100 105 110
 Leu Gln Asp Gly Cys Phe Ile Tyr Lys Val Lys Phe Ile Gly Val Asn
 115 120 125
 Phe Pro Ser Asp Gly Pro Val Met Gln Lys Lys Thr Met Gly Trp Glu
 130 135 140

WO 00/46233

PCT/AU00/00056

5

Ala Ser Thr Lys Arg Leu Tyr Pro Arg Asp Gly Val Leu Lys Gly Glu
145 150 155 160

Ile His Lys Ala Leu Lys Leu Lys Asp Gly Gly His Tyr Leu Val Glu
165 170 175

Phe Lys Ser Ile Tyr Met Ala Lys Lys Pro Val Gln Leu Pro Gly Tyr
180 185 190

Tyr Tyr Val Asp Ser Lys Leu Asp Ile Thr Ser His Asn Glu Asp Tyr
195 200 205

Thr Ile Val Glu Gln Tyr Glu Arg Thr Glu Gly Arg His His Leu Phe
210 215 220

Leu
225

<210> 10
<211> 230
<212> PRT
<213> Discosoma sp.

<400> 10
Met Ser Lys Gly Glu Glu Leu Phe Thr Gly Val Val Pro Ile Leu Val
1 5 10 15

Glu Leu Asp Gly Asp Val Asn Gly His Lys Phe Ser Val Ser Gly Glu
20 25 30

Gly Glu Gly Asp Ala Thr Tyr Gly Lys Leu Thr Leu Lys Phe Ile Cys
35 40 45

Thr Thr Gly Lys Leu Pro Val Pro Trp Pro Thr Leu Val Thr Thr Phe
50 55 60

Ser Tyr Gly Val Gln Cys Phe Ser Arg Tyr Pro Asp His Met Lys Arg
65 70 75 80

His Asp Phe Phe Lys Ser Ala Met Pro Glu Gly Tyr Val Gln Glu Arg
85 90 95

Thr Ile Phe Phe Lys Asp Asp Gly Asn Tyr Lys Thr Arg Ala Glu Val
100 105 110

Lys Phe Glu Gly Asp Thr Leu Val Asn Arg Ile Glu Leu Lys Gly Ile
115 120 125

Asp Phe Lys Glu Asp Gly Asn Ile Leu Gly His Lys Leu Glu Tyr Asn
130 135 140

Tyr Asn Ser His Asn Val Tyr Ile Met Ala Asp Lys Gln Lys Asn Gly
145 150 155 160

Ile Lys Val Asn Phe Lys Ile Arg His Asn Ile Glu Asp Gly Ser Val
165 170 175

Gln Leu Ala Asp His Tyr Gln Gln Asn Thr Pro Ile Gly Asp Gly Pro
180 185 190

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

WO 00/46233

PCT/AU00/00056

6

Val Leu Leu Pro Asp Asn His Tyr Leu Ser Thr Gln Ser Ala Leu Ser
 195 200 205

Lys Asp Pro Asn Glu Lys Arg Asp His Met Val Leu Leu Glu Phe Val
 210 215 220

Thr Ala Ala Gly Ile Thr
 225 230

<210> 11
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: PCR primers

<400> 11
 tccgttatcg ctaaacagat 20

<210> 12
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: PCR primers

<400> 12
 tttgtgcett gatttgactc 20

<210> 13
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: PCR primers

<400> 13
 cgccactgog tatttgtgcc 20

<210> 14
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: PCR primers

<400> 14
 ggcgaccaca ggtttgcgtg 20

<210> 15
 <211> 30

WO 00/46233

PCT/AU00/00056

7

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR primers

<400> 15

tccgttatcg ctaaacagat gacctacaaa

30